0001537561 false --09-30 2023 Q2 1 3 0 0 0 0 5 7 5 8 4 248 35 200 00015375612022-10-012023-03-31 thunderdome:item iso4217:USD 0001537561us-gaap:SubsequentEventMember2023-05-18 0001537561us-gaap:SubsequentEventMember2023-05-152023-05-15 xbrli:shares 0001537561arch:ThirdInducementSharesMemberus-gaap:SubsequentEventMember2023-05-15 0001537561arch:WarrantSharesMemberus-gaap:SubsequentEventMember2023-05-15 0001537561arch:ThirdNotesMemberus-gaap:SubsequentEventMember2023-05-15 0001537561arch:InConnectionWithNearTermCapitalRaiseMemberus-gaap:SubsequentEventMember2023-04-012023-05-31 0001537561arch:ThirdPartyMemberus-gaap:SubsequentEventMember2023-04-012023-05-31 0001537561arch:SingleInvestorMemberus-gaap:SubsequentEventMember2023-04-012023-05-31 00015375612022-10-012023-05-31 0001537561us-gaap:SubsequentEventMember2023-04-012023-05-31 0001537561arch:Series12ConvertibleNotesMember2021-10-012022-03-31 0001537561arch:Series12ConvertibleNotesMember2022-10-012023-03-31 0001537561arch:Series12ConvertibleNotesMember2022-01-012022-03-31 0001537561arch:Series12ConvertibleNotesMember2023-01-012023-03-31 xbrli:pure 0001537561arch:Series2ConvertibleNotesMember2023-03-09 0001537561arch:Series2ConvertibleNotesMember2023-03-10 0001537561arch:Series2NotesConvertedToSeniorSecuredConvertibleNotesMember2022-07-062022-07-06 0001537561arch:Series2ConvertibleNotesMember2022-07-07 utr:Y 0001537561arch:SeriesJWarrantsMember2022-09-30 iso4217:USDxbrli:shares 0001537561arch:SeriesJWarrantsMember2022-06-22 0001537561arch:SeriesJWarrantsMember2020-06-22 0001537561arch:SeriesDWarrantsMember2020-06-222020-06-22 0001537561arch:SeriesJWarrantsMember2020-11-06 0001537561arch:SeriesDWarrantsMember2020-06-032020-06-03 0001537561arch:SeriesDWarrantMember2015-06-30 0001537561us-gaap:PrivatePlacementMember2015-06-30 0001537561us-gaap:PrivatePlacementMember2015-06-222015-06-30 0001537561arch:Series1ConvertibleNotesMembersrt:MaximumMember2020-06-04 0001537561arch:Series2ConvertibleNotesMember2020-11-06 0001537561arch:Series1ConvertibleNotesMember2020-06-04 0001537561arch:Series12ConvertibleNotesMember2020-11-062020-11-06 0001537561arch:SecondPlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2023-01-18 0001537561arch:SecondWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2023-01-18 0001537561arch:SecondPlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-01-18 0001537561arch:SecondWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-01-18 0001537561arch:SecondPlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-01-18 0001537561arch:SecondWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-01-18 0001537561arch:SecondPlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2023-01-18 0001537561arch:SecondWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2023-01-18 0001537561arch:SecondPlacementAgentWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2023-01-18 0001537561arch:SecondWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2023-01-18 0001537561arch:SecondPlacementAgentWarrantsMember2023-01-18 0001537561arch:SecondWarrantsMember2023-01-18 0001537561arch:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-07-06 0001537561arch:InvestorWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-07-06 0001537561arch:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-07-06 0001537561arch:InvestorWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-07-06 0001537561arch:PlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-07-06 0001537561arch:InvestorWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-07-06 0001537561arch:PlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2022-07-06 0001537561arch:InvestorWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2022-07-06 0001537561arch:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2022-07-06 0001537561arch:InvestorWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2022-07-06 0001537561arch:PlacementAgentWarrantsMember2022-07-06 0001537561arch:InvestorWarrantsMember2022-07-06 0001537561arch:SecondNotesMember2023-03-31 0001537561arch:Notes2022Member2022-09-30 0001537561arch:Notes2022Member2023-03-31 0001537561arch:SecondPlacementAgentWarrantsMember2023-03-31 0001537561arch:PlacementAgentWarrantsMember2023-03-31 0001537561arch:SeniorSecuredConvertiblePromissoryNotesMember2023-03-31 0001537561arch:SecondWarrantsMember2023-01-182023-01-18 00015375612023-01-182023-01-18 0001537561arch:Warrant2022Member2021-10-012022-09-30 0001537561arch:InducementShares2022Member2021-10-012022-09-30 0001537561arch:The2022NotesAndSecondNotesMember2022-10-012023-03-31 0001537561arch:The2022NotesAndSecondNotesMember2023-01-012023-03-31 0001537561arch:Notes2022Member2022-07-07 0001537561arch:Notes2022Member2022-07-072022-07-07 0001537561arch:Series1ConvertibleNotesMember2022-07-07 0001537561arch:PlacementAgent2022SecondNotesMember2022-09-30 0001537561arch:PlacementAgent2022SecondNotesMember2021-10-012022-09-30 0001537561arch:CertainInvestorsMemberarch:PlacementAgent2022SecondNotesMember2021-10-012022-09-30 0001537561arch:PlacementAgent2022SecondNotesMember2022-09-30 0001537561arch:SeniorSecuredConvertibleNotesMemberarch:BoardMemberAndExecutiveOfficerMember2021-10-012022-09-30 0001537561arch:PrivatePlacementNotesMember2022-07-072022-07-07 0001537561arch:PlacementAgent2022Member2022-09-30 0001537561arch:PlacementAgent2022Member2021-10-012022-09-30 0001537561arch:CertainInvestorsMemberarch:PlacementAgent2022Member2021-10-012022-09-30 0001537561arch:PlacementAgent2022Member2022-09-30 0001537561arch:Notes2022Member2022-07-072022-07-07 0001537561arch:Warrant2022Membersrt:MaximumMember2022-07-07 0001537561arch:Warrant2022Member2022-07-07 0001537561arch:Notes2022Membersrt:MaximumMember2022-07-07 0001537561arch:Notes2022Membersrt:MinimumMember2022-07-07 00015375612023-01-182023-11-08 0001537561arch:SecuritiesPurchaseAgreementMember2023-01-182023-01-18 0001537561arch:SecondNotesMember2023-01-18 00015375612022-07-072022-07-07 0001537561arch:PlacementAgentWarrant2022Member2022-07-07 00015375612022-07-07 0001537561arch:SecuritiesPurchaseAgreementMember2022-07-072022-07-07 0001537561arch:WarrantSharesMember2022-07-07 00015375612021-02-172021-02-17 0001537561arch:PlacementAgent2WarrantsMember2023-03-31 0001537561arch:SeriesKWarrantMember2023-03-31 0001537561arch:SeriesKAndPlacementAgent2WarrantsMember2022-10-012023-03-31 0001537561arch:SeriesKAndPlacementAgent2WarrantsMember2023-01-012023-03-31 0001537561arch:PlacementAgent2WarrantsMember2021-02-11 0001537561arch:ClearingExpensesMemberarch:The2021RegisteredDirectOfferingMember2021-02-11 0001537561arch:FeesAndExpensesOfLegalCounselAndOtherOutofpocketExpensesMemberarch:The2021RegisteredDirectOfferingMember2021-02-11 0001537561arch:NonaccountableExpenseFeeMemberarch:The2021RegisteredDirectOfferingMember2021-02-11 0001537561arch:CertainInvestorsWithPreexistingRelationshipsMemberarch:The2021RegisteredDirectOfferingMember2021-02-11 0001537561arch:ParticipatingInvestorsMemberarch:The2021RegisteredDirectOfferingMember2021-02-11 0001537561arch:The2021RegisteredDirectOfferingMember2021-02-112021-02-11 0001537561arch:SeriesKWarrantMember2021-02-11 0001537561arch:The2021RegisteredDirectOfferingMember2021-02-11 0001537561arch:RegisteredDirectOfferingOctober2019Member2019-10-182019-10-18 0001537561arch:SeriesIWarrantMember2023-03-31 0001537561arch:SeriesIAndPlacementAgentWarrantsMember2022-10-012023-03-31 0001537561arch:SeriesIAndPlacementAgentWarrantsMember2023-01-012023-03-31 0001537561arch:SeriesIWarrantMember2019-10-162019-10-16 0001537561arch:SeriesIWarrantMembersrt:MaximumMember2019-10-162019-10-16 0001537561arch:SeriesIWarrantMembersrt:MinimumMember2019-10-162019-10-16 0001537561arch:RegisteredDirectOffering2019Member2019-10-162019-10-16 00015375612023-03-31 0001537561arch:October2019PlacementAgentWarrantsMember2019-10-16 0001537561arch:SeriesIWarrantMember2019-10-16 0001537561arch:RegisteredDirectOffering2019Member2019-10-16 0001537561arch:SeriesHWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExpectedTermMember2022-09-30 0001537561arch:SeriesGWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExpectedTermMember2022-09-30 0001537561arch:SeriesHWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-09-30 0001537561arch:SeriesGWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-09-30 0001537561arch:SeriesHWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-30 0001537561arch:SeriesGWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-30 0001537561arch:SeriesHWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputPriceVolatilityMember2022-09-30 0001537561arch:SeriesGWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputPriceVolatilityMember2022-09-30 0001537561arch:SeriesHWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExercisePriceMember2022-09-30 0001537561arch:SeriesGWarrantDerivativeMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExercisePriceMember2022-09-30 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputSharePriceMember2022-09-30 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExpectedTermMember2023-03-10 0001537561arch:SeriesGWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExpectedTermMember2023-03-10 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputInceptionDiscountRateMember2023-03-10 0001537561arch:SeriesGWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputInceptionDiscountRateMember2023-03-10 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-03-10 0001537561arch:SeriesGWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-03-10 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputPriceVolatilityMember2023-03-10 0001537561arch:SeriesGWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputPriceVolatilityMember2023-03-10 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExercisePriceMember2023-03-10 0001537561arch:SeriesGWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputExercisePriceMember2023-03-10 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputSharePriceMember2023-03-10 0001537561arch:SeriesGWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:MeasurementInputSharePriceMember2023-03-10 0001537561arch:SeriesHWarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-03-31 0001537561arch:SeriesGWarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-03-31 0001537561arch:SeriesFWarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-03-31 0001537561arch:SeriesHWarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-10-012022-03-31 0001537561arch:SeriesGWarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-10-012022-03-31 0001537561arch:SeriesFWarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-10-012022-03-31 0001537561arch:SeriesHWarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-09-30 0001537561arch:SeriesGWarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-09-30 0001537561arch:SeriesFWarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-09-30 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-03-31 0001537561arch:SeriesGWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-03-31 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-01-012023-03-31 0001537561arch:SeriesGWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-01-012023-03-31 0001537561arch:SeriesHWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-12-31 0001537561arch:SeriesGWarrantMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-12-31 0001537561arch:DerivativeWarrantLiabilityMember2021-10-012022-03-31 0001537561arch:DerivativeWarrantLiabilityMember2022-10-012023-03-31 0001537561arch:ExtinguishmentOfDerivativeLiabilitiesForWarrantsMember2023-01-012023-03-31 00015375612023-01-012023-03-31 0001537561arch:SeriesHWarrantMember2023-03-102023-03-10 0001537561arch:SeriesGWarrantMember2023-03-102023-03-10 0001537561arch:SeriesHWarrantMember2023-03-10 0001537561arch:SeriesGWarrantMember2023-03-10 00015375612023-03-10 0001537561arch:DerivativeWarrantLiabilityMember2019-05-12 0001537561arch:SeriesHWarrantMember2019-05-12 0001537561arch:SeriesGWarrantMember2018-06-28 0001537561arch:SeriesFWarrantMember2017-06-22 0001537561arch:SeriesFWarrantMember2021-10-012022-09-30 0001537561arch:ClassOfSeriesHWarrantMember2019-05-12 0001537561arch:The2019SPAMember2019-05-12 0001537561arch:The2019SPAMember2019-05-122019-05-12 0001537561arch:ClassOfSeriesGWarrantMemberarch:RegisteredDirectOffering2018Member2018-06-28 0001537561arch:ClassOfSeriesGWarrantMember2018-06-28 0001537561arch:The2018SPAMember2018-06-28 0001537561arch:The2018SPAMember2018-06-282018-06-28 0001537561arch:SeriesFWarrantMember2017-02-20 0001537561arch:ClassOfSeriesFWarrantMember2017-02-20 0001537561arch:The2017SPAMember2017-02-20 0001537561arch:The2017SPAMember2017-02-202017-02-20 00015375612016-09-30 0001537561arch:NonEmployeeRestrictedSharesMember2021-10-012022-03-31 0001537561arch:NonEmployeeRestrictedSharesMember2022-10-012023-03-31 0001537561arch:NonEmployeeRestrictedSharesMember2022-01-012022-03-31 0001537561arch:NonEmployeeRestrictedSharesMember2023-01-012023-03-31 0001537561arch:The2013PlanMember2022-03-31 0001537561arch:The2013PlanMember2023-03-31 0001537561arch:The2013PlanMember2021-10-012022-03-31 0001537561arch:The2013PlanMember2022-10-012023-03-31 0001537561arch:The2013PlanMember2021-09-30 0001537561arch:The2013PlanMember2022-09-30 00015375612022-03-31 00015375612022-01-012022-03-31 00015375612021-12-31 00015375612022-12-31 0001537561arch:The2013PlanMember2023-01-012023-03-31 0001537561us-gaap:RestrictedStockMember2021-12-31 0001537561arch:The2013PlanMember2022-12-31 0001537561us-gaap:GeneralAndAdministrativeExpenseMember2021-10-012022-03-31 0001537561us-gaap:GeneralAndAdministrativeExpenseMember2022-10-012023-03-31 0001537561us-gaap:ResearchAndDevelopmentExpenseMember2021-10-012022-03-31 0001537561us-gaap:ResearchAndDevelopmentExpenseMember2022-10-012023-03-31 0001537561arch:EmployeesDirectorsAndConsultantsMember2021-10-012022-03-31 0001537561arch:EmployeesDirectorsAndConsultantsMember2022-10-012023-03-31 0001537561us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-31 0001537561us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-31 0001537561us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-31 0001537561us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-31 0001537561arch:EmployeesDirectorsAndConsultantsMember2022-01-012022-03-31 0001537561arch:EmployeesDirectorsAndConsultantsMember2023-01-012023-03-31 00015375612022-09-30 00015375612021-10-012022-09-30 0001537561us-gaap:RestrictedStockMemberarch:The2013PlanMemberarch:ConsultantsMember2022-10-012023-03-31 0001537561us-gaap:RestrictedStockMemberarch:The2013PlanMemberarch:BoardOfDirectorsAndManagementMember2022-10-012023-03-31 0001537561arch:The2013PlanMember2022-10-01 0001537561arch:The2013PlanMember2013-06-18 0001537561arch:The2013PlanMember2013-06-182013-06-18 0001537561arch:InsurancePremiumFinancingMember2022-09-30 0001537561arch:InsurancePremiumFinancingMember2023-03-31 0001537561arch:InsurancePremiumFinancingMember2022-07-012022-07-31 0001537561arch:InsurancePremiumFinancingMember2022-07-31 00015375612021-10-012022-03-31 0001537561us-gaap:TechnologyEquipmentMember2022-09-30 0001537561us-gaap:TechnologyEquipmentMember2023-03-31 0001537561us-gaap:ComputerEquipmentMember2022-09-30 0001537561us-gaap:ComputerEquipmentMember2023-03-31 0001537561us-gaap:LeaseholdImprovementsMember2022-09-30 0001537561us-gaap:LeaseholdImprovementsMember2023-03-31 0001537561us-gaap:FurnitureAndFixturesMember2022-09-30 0001537561us-gaap:FurnitureAndFixturesMember2023-03-31 0001537561arch:ReverseStockSplitMember2023-01-172023-01-17 0001537561arch:PlacementAgentWarrantsMember2021-10-012022-03-31 0001537561arch:PlacementAgentWarrantsMember2022-10-012023-03-31 0001537561arch:SecondWarrantsMember2021-10-012022-03-31 0001537561arch:SecondWarrantsMember2022-10-012023-03-31 00015375612021-09-30 0001537561us-gaap:RetainedEarningsMember2022-03-31 0001537561us-gaap:AdditionalPaidInCapitalMember2022-03-31 0001537561us-gaap:CommonStockMember2022-03-31 0001537561us-gaap:RetainedEarningsMember2021-10-012022-03-31 0001537561us-gaap:AdditionalPaidInCapitalMember2021-10-012022-03-31 0001537561us-gaap:CommonStockMember2021-10-012022-03-31 0001537561us-gaap:RetainedEarningsMember2021-09-30 0001537561us-gaap:AdditionalPaidInCapitalMember2021-09-30 0001537561us-gaap:CommonStockMember2021-09-30 0001537561us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-31 0001537561us-gaap:RetainedEarningsMember2022-01-012022-03-31 0001537561us-gaap:CommonStockMember2022-01-012022-03-31 0001537561us-gaap:RetainedEarningsMember2021-12-31 0001537561us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001537561us-gaap:CommonStockMember2021-12-31 0001537561us-gaap:RetainedEarningsMember2023-03-31 0001537561us-gaap:AdditionalPaidInCapitalMember2023-03-31 0001537561us-gaap:CommonStockMember2023-03-31 0001537561us-gaap:AdditionalPaidInCapitalMember2022-10-012023-03-31 0001537561us-gaap:CommonStockMember2022-10-012023-03-31 0001537561us-gaap:RetainedEarningsMember2022-10-012023-03-31 0001537561us-gaap:RetainedEarningsMember2022-09-30 0001537561us-gaap:AdditionalPaidInCapitalMember2022-09-30 0001537561us-gaap:CommonStockMember2022-09-30 0001537561us-gaap:RetainedEarningsMember2023-01-012023-03-31 0001537561us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0001537561us-gaap:CommonStockMember2023-01-012023-03-31 0001537561us-gaap:RetainedEarningsMember2022-12-31 0001537561us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001537561us-gaap:CommonStockMember2022-12-31 0001537561arch:SeniorSecuredConvertibleNotesMember2022-09-30 0001537561arch:SeniorSecuredConvertibleNotesMember2023-03-31 0001537561arch:ConvertibleNotesPayableSeriesTwoMember2022-09-30 0001537561arch:ConvertibleNotesPayableSeriesTwoMember2023-03-31 0001537561arch:UnsecuredConvertibleNotesMember2022-09-30 0001537561arch:UnsecuredConvertibleNotesMember2023-03-31 0001537561arch:ConvertibleNotesPayableSeriesOneMember2022-09-30 0001537561arch:ConvertibleNotesPayableSeriesOneMember2023-03-31 00015375612023-05-19 0001537561arch:InsurancePremiumFinancingMember2022-10-012023-03-31 0001537561arch:The2021RegisteredDirectOfferingMember2022-10-012023-03-31 0001537561arch:Notes2022Member2022-10-012023-03-31
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT

 

For the transition period from N/A to N/A

 

Commission File Number: 000-54986

 

ARCH THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

46-0524102

(State or other jurisdiction of incorporation or
organization)

 

(I.R.S. Employer Identification No.)

     

235 Walnut Street, Suite 6

   

Framingham, MA

 

01702

(Address of principal executive offices)

 

(Zip Code)

 

(617) 431-2313

Registrant’s telephone number, including area code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N|A

N|A

N|A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act

 

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

 

As of May 22, 2023, 1,285,213 shares of the registrant’s common stock were outstanding.

 

 

 

 

 

ARCH THERAPEUTICS, INC.

Quarterly Report on Form 10-Q

 

 

TABLE OF CONTENTS

 

 

PART I – FINANCIAL INFORMATION

 
   

Item 1. Consolidated Financial Statements

1

   

Consolidated Balance Sheets as of March 31, 2023 (unaudited) and September 30, 2022

1

   

Consolidated Statements of Operations for the Three and Six months ended March 31, 2023 and March 31, 2022 (unaudited)

2

   

Consolidated Statements of Changes in Stockholders’ Deficit for the Three and Six months ended March 31, 2023 and March 31, 2022 (unaudited)

3

   

Consolidated Statements of Cash Flows for the Six months ended March 31, 2023 and March 31, 2022 (unaudited)

4

   

Notes to Consolidated Financial Statements (unaudited)

5

   

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

   

Item 3. Quantitative and Qualitative Disclosures About Market Risk

29

   

Item 4. Controls and Procedures

29

   

PART II - OTHER INFORMATION

30

   

Item 1. Legal Proceedings

30

   

Item 1A. Risk Factors

30

   

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

30

   

Item 6. Exhibits

33

 

 

 

 

 

Arch Therapeutics, Inc. and Subsidiary

Consolidated Balance Sheets

As of March 31, 2023 (Unaudited) and September 30, 2022

 

 

   

March 31,

2023

   

September 30,

2022

 
ASSETS                
Current assets:                

Cash

  $ 29,495     $ 746,940  

Inventory

    1,402,384       1,414,848  

Prepaid expenses and other current assets

    156,349       436,407  

Total current assets

    1,588,228       2,598,195  
                 
Long-term assets:                

Property and equipment, net

    1,001       2,044  

Other assets

    3,500       3,500  

Total long-term assets

    4,501       5,544  
                 

Total assets

  $ 1,592,729     $ 2,603,739  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT                
Current liabilities:                

Accounts payable

  $ 2,425,894     $ 1,328,000  

Shareholder advances

    230,000       -  

Accrued expenses and other liabilities

    205,792       318,505  

Insurance premium financing

    35,419       247,933  

Current Portion of Series 2 convertible note

    550,000       550,000  
Current Portion of Series 1 convertible note     450,000       -  
Current Portion of Unsecured convertible notes     981,317       -  

Current Portion of 2022 Notes

    2,454,683       -  

Current Portion of Accrued Interest

    645,712       127,781  

Current portion of derivative liability

    -       748,275  

Total current liabilities

    7,978,817       3,320,494  
                 
Long-term liabilities:                
Unsecured convertible notes     -       699,781  

Series 2 convertible notes

    -       450,000  

2022 Notes

    -       1,662,492  

Accrued interest

    -       204,575  

Derivative liability

    -       459,200  

Total long-term liabilities

    -       3,476,048  
                 

Total liabilities

    7,978,817       6,796,542  
                 
Commitments and contingencies            
                 
Stockholders’ deficit:                

Common stock, $0.001 par value, 12,000,000 and 4,000,000 shares authorized as of March 31, 2023 and September 30, 2022, 1,274,605 and 1,252,665 shares issued as of March 31, 2023 and September 30, 2022 and 1,274,605 and 1,249,432 shares outstanding as of March 31, 2023 and September 30, 2022

    1,275       1,252  

Additional paid-in capital

    51,387,943       50,878,718  

Accumulated deficit

    (57,775,306

)

    (55,072,773

)

Total stockholders’ deficit

    (6,386,088

)

    (4,192,803

)

                 

Total liabilities and stockholders’ deficit

  $ 1,592,729     $ 2,603,739  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

-1-

 

 

 

Arch Therapeutics, Inc. and Subsidiary

Consolidated Statements of Operations (Unaudited)

For the Three and Six Months Ended March 31, 2023 and 2022

 

 

   

Three Months

Ended March 31,

2023

   

Three Months

Ended March 31,

2022

   

Six Months

Ended March 31,

2023

   

Six Months

Ended March 31,

2022

 
                                 
                                 

Revenue

  $ 16,654     $ 3,130     $ 22,914     $ 7,826  
                                 
Operating expenses:                                

Cost of revenues

    18,718       17,430       36,353       34,223  

Selling, general and administrative expenses

    1,252,786       1,208,910       2,355,701       2,472,013  

Research and development expenses

    170,634       527,656       332,087       762,274  

Total costs and expenses

    1,442,138       1,753,996       2,724,141       3,268,510  
                                 

Loss from operations

    (1,425,484

)

    (1,750,866

)

    (2,701,227 )     (3,260,684 )
                                 
Other income (expense):                                

Interest expense

    (635,190

)

    (39,452

)

    (1,159,503 )     (79,781 )
Gain on extinguishment of derivative liabilities     1,158,197       -       1,158,197       -  
Expiration of derivative liability/Series F warrant     -       1,000,000       -       1,000,000  
Total other income (expense)     523,007       960,548       (1,306 )     920,219  
                                 

Net loss

  $ (902,477

)

  $ (790,318

)

  $ (2,702,533 )   $ (2,340,465 )
                                 
Loss per share - basic and diluted                                

Net loss per common share - basic and diluted

  $ (0.71 )   $ (0.67 )   $ (2.15 )   $ (1.98 )

Weighted common shares - basic and diluted

    1,263,437       1,184,328       1,255,373       1,184,030  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

-2-

 

 

 

Arch Therapeutics, Inc. and Subsidiary

Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)

For the Three and Six Months Ended March 31, 2023 and 2022

 

 

                   

Additional

           

Total

 
   

Common Stock

   

Paid-in

   

Accumulated

   

Stockholders'

 

Three Months Ended March 31, 2023

  Shares     Amount     Capital     Deficit     Deficit  
                                         

Balance at December 31, 2022

    1,252,665     $ 1,252     $ 50,982,744     $ (56,872,829 )     (5,888,833 )
                                         

Net loss

    -       -       -       (902,477 )     (902,477 )

Vesting of restricted stock

    250       -       -       -       -  

Stock-based compensation expense

    -       -       68,524       -       68,524  

Issuance of common stock and warrants, net of financing costs

    9,598       10       287,410       -       287,420  

Exchange of warrants into common stock

    12,019       13       49,265       -       49,278  

Balance at March 31, 2023

    1,274,532     $ 1,275     $ 51,387,943     $ (57,775,306 )   $ (6,386,088 )

 

                   

Additional

           

Total

 
   

Common Stock

   

Paid-in

   

Accumulated

   

Stockholders'

 

Six Months Ended March 31, 2023

 

Shares

   

Amount

   

Capital

   

Deficit

   

Deficit

 
                                         

Balance at September 30, 2022

    1,252,665     $ 1,252     $ 50,878,718     $ (55,072,773 )     (4,192,803 )
                                         

Net loss

    -       -       -       (2,702,533 )     (2,702,533 )

Vesting of restricted stock

    250       -       -       -       -  

Stock-based compensation expense

    -       -       172,550       -       172,550  

Issuance of common stock and warrants, net of financing costs

    9,598       10       287,410       -       287,420  

Exchange of warrants into common stock

    12,019       13       49,265               49,278  

Balance at March 31, 2023

    1,274,532     $ 1,275     $ 51,387,943     $ (57,775,306 )   $ (6,386,088 )

 

                   

Additional

           

Total

 
   

Common Stock

   

Paid-in

   

Accumulated

   

Stockholders'

 

Three Months Ended March 31, 2022

  Shares     Amount     Capital     Deficit     Equity (Deficit)  
                                         

Balance at December 31, 2021

    1,183,974     $ 1,184     $ 48,922,204     $ (51,347,066 )   $ (2,423,678 )
                                         

Net loss

    -       -       -       (790,318 )     (790,318 )

Vesting of restricted stock

    625       1       (1 )     -       -  

Stock-based compensation expense

    -       -       154,572       -       154,572  

Balance at March 31, 2022

    1,184,599     $ 1,185     $ 49,076,775     $ (52,137,384

)

  $ (3,059,424

)

 

                   

Additional

           

Total

 
   

Common Stock

   

Paid-in

   

Accumulated

   

Stockholders'

 

Six Months Ended March 31, 2022

 

Shares

   

Amount

   

Capital

   

Deficit

   

Deficit

 
                                         

Balance at September 30, 2021

    1,183,599     $ 1,184     $ 48,770,061     $ (49,796,919 )   $ (1,025,674 )
                                         

Net loss

    -       -       -       (2,340,465 )     (2,340,465 )

Vesting of restricted stock

    1,000       1       (1 )     -       -  

Stock-based compensation expense

    -       -       306,715       -       306,715  

Balance at March 31, 2022

    1,184,599     $ 1,185     $ 49,076,775     $ (52,137,384 )   $ (3,059,424 )

 

The accompanying notes are an integral part of these consolidated financial statements.

 

-3-

 

 

 

Arch Therapeutics, Inc. and Subsidiary

Consolidated Statements of Cash Flows (Unaudited)

For the Six Months Ended March 31, 2023 and 2022

 

 

   

Six Months

Ended March 31,

2023

   

Six Months

Ended March 31,

2022

 
Cash flows from operating activities:                

Net loss

  $ (2,702,533

)

  $ (2,340,465

)

Adjustments to reconcile net loss to cash used in operating activities:                

Depreciation

    1,043       1,598  

Stock-based compensation

    172,550       306,715  

Decrease to fair value of derivative

    -       (1,000,000 )
Gain on extinguishment of derivative liabilities     (1,158,197 )     -  

Accretion of discount and debt issuance costs on 2022 Notes and Unsecured convertible notes

    846,147       -  

Inventory obsolescence charge

    -       248,073  
Changes in operating assets and liabilities:                
(Increase) decrease in:                

Inventory

    12,464       (351,876 )

Prepaid expenses and other current assets

    280,058       127,080  
Increase (decrease) in:                

Accounts payable

    1,097,894       879,995  

Accrued interest

    313,356       79,781  

Accrued expenses and other current liabilities

    (112,713

)

    (163,135

)

Net cash used in operating activities

    (1,249,931

)

    (2,212,234

)

                 
Cash flows from financing activities:                

Repayment of insurance premium financing

    (212,514

)

    -  

Proceeds from shareholder advances

    230,000       -  
Proceeds from Unsecured convertible notes     515,000       -  

Net cash provided by financing activities

    532,486       -  
                 

Net decrease in cash

    (717,445 )     (2,212,234 )
                 

Cash, beginning of year

    746,940       2,266,639  
                 

Cash, end of period

  $ 29,495     $ 54,405  
                 
Non-cash financing activities:                

Exchange of Series G and Series H warrants for common stock

  $ 49,278     $ -  

Issuance of restricted stock

  $ 3,019     $ 19,887  
Fair value of warrants issued - second close   $ 256,439     $ -  
Fair value of inducement shares issued - second close   $ 25,840     $ -  
Fair value of placement agent warrants - second close   $ 28,093     $ -  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

-4-

 

 

ARCH THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited) 

 

 

 

1. BASIS OF PRESENTATION AND DESCRIPTION OF BUSINESS

 

Organization and Description of Business

 

Arch Therapeutics, Inc. (together with its subsidiary, the “Company” or “Arch”) was incorporated under the laws of the State of Nevada on September 16, 2009, under the name “Almah, Inc.”. Effective June 26, 2013, the Company completed a merger (the “Merger”) with Arch Biosurgery, Inc. (formerly known as Arch Therapeutics, Inc.), a Massachusetts corporation (“ABS”), and Arch Acquisition Corporation (“Merger Sub”), the Company’s wholly owned subsidiary formed for the purpose of the transaction, pursuant to which Merger Sub merged with and into ABS and ABS thereby became the wholly owned subsidiary of the Company. As a result of the acquisition of ABS, the Company abandoned its prior business plan and changed its operations to the business of a biotechnology company. The Company’s principal offices are located in Framingham, Massachusetts.

 

ABS was incorporated under the laws of the Commonwealth of Massachusetts on March 6, 2006, as Clear Nano Solutions, Inc. On April 7, 2008, ABS changed its name from Clear Nano Solutions, Inc. to Arch Therapeutics, Inc. Effective upon the closing of the Merger, ABS changed its name from Arch Therapeutics, Inc. to Arch Biosurgery, Inc.

 

In the first quarter of 2021, the Company commenced commercial sales of our first product, AC5® Advanced Wound System, and has devoted substantially all of the Company’s operational effort to the research, development and regulatory programs necessary to turn the Company’s core technology into commercial products. To date, the Company has principally raised capital through the issuance of convertible debt, and the issuance of units consisting of its common stock, $0.001 par value per share (“Common Stock”) and warrants to purchase Common Stock (“warrants”).

 

The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential future products. However, there can be no assurance that the Company will be successful in securing additional resources when needed, on terms acceptable to the Company, if at all. Therefore, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments related to the recoverability of assets that might be necessary despite this uncertainty.

 

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The interim consolidated financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s results of operations and financial position for the interim periods.

 

Although the Company believes that the disclosures in these unaudited interim consolidated financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022, filed with the SEC on December 28, 2022 (the “Annual Report”).

 

For a complete summary of the Company’s significant accounting policies, please refer to Note 2 included in Item 8 of the Company’s Annual Report. There have been no material changes to the Company’s significant accounting policies during the six months ended March 31, 2023.

 

Basis of Presentation

 

The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation.

 

On January 6, 2023, the directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 1:200, effective January 17, 2023 (the “Reverse Share Split”). All information included in these consolidated financial statements has been adjusted, on a retrospective basis, to reflect the Reverse Share Split, unless otherwise stated. All outstanding securities entitling their holders to purchase shares of Common Stock or acquire shares of Common Stock, including stock options, restricted stock units, and warrants, were adjusted as a result of the Reverse Stock Split, as required by the terms of those securities.

 

Use of Estimates

 

Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.

 

-5-

 

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents as of March 31, 2023 and September 30, 2022.

 

Inventories

 

Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.

 

Property and Equipment

 

Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred.

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant and Equipment. For assets that are to be held and used, impairment is recognized when the estimated undiscounted cash flows associated with the asset or group of assets is less than their carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value. For the six months ended March 31, 2023 and 2022 there has not been any impairment of long-lived assets.

 

Leases

 

The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease does not provide an implicit interest rate, the Company used an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

Income Taxes

 

In accordance with FASB ASC Topic 740, Income Taxes, the Company recognizes deferred tax assets and liabilities for the expected future tax consequences or events that have been included in the Company’s consolidated financial statements and/or tax returns. Deferred tax assets and liabilities are based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

 

The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not that a loss will be incurred related to these matters and the amount of the loss is reasonably determinable.

 

Revenue

 

In accordance with FASB ASC Topic 606, Revenue Recognition, the Company recognizes revenue through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied.

 

The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third-party warehouse.

 

-6-

 

 

Cost of Revenue

 

Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense.

 

Research and Development

 

The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred.

 

Accounting for Stock-Based Compensation

 

The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation (“ASC 718”), which requires all share-based payments be recognized in the consolidated financial statements based on their fair values. In accordance with ASC 718, the Company has elected to use the Black-Scholes Option Pricing Model (the “Black-Scholes Model”) to determine the fair value of options granted and recognizes the compensation cost of share-based awards on a straight-line basis over the vesting period of the award.

 

The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the Company’s awards. The dividend yield assumption is based on history and the expectation of paying no dividends. Stock-based compensation expense, when recognized in the consolidated financial statements, is based on awards that are ultimately expected to vest.

 

Fair Value Measurements

 

The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures, including those that are recognized or disclosed in the consolidated financial statements at fair value on a recurring basis. The standard created a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3 inputs are unobservable inputs that reflect the Company’s own views about the assumptions market participants would use in pricing the asset or liability.

 

At March 31, 2023 and September 30, 2022, the carrying amounts of cash, accounts payables and accrued expense and other liabilities approximate fair value because of their short-term nature. The carrying amounts for the Series Convertible Notes (See Note 12), 2022 Notes (see Note 11), and Second Notes (see Note 11) approximate fair value because borrowing rates and terms are similar to comparable market participants.

 

Derivative Liabilities

 

The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging (“ASC 815”). Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate. During the three months ended March 31, 2023, $1,158,197 was recorded to gain on extinguishment of derivative liability for the exchange of the Series G warrants and Series H warrants and $49,278 was recorded as part of shareholder's deficit.

 

Complex Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option-pricing model or other acceptable valuation models, including Monte-Carlo simulations. Derivative instruments are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is re-assessed at the end of each reporting period.

 

-7-

 

 

The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and warrants, including options or warrants to non-employees in exchange for consulting or other services performed.

 

The Company accounts for its common stock warrants in accordance with Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). Based upon the provisions of ASC 815, the Company accounts for common stock warrants as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement, or it fails the equity classification criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified as equity. Common stock warrants classified as liabilities are initially recorded at fair value on the grant date and remeasured at fair value each balance sheet date with the offset adjustments recorded in change in fair value of warrant liability within the consolidated statements of operations. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.

 

Financial Statement Reclassification

 

Certain balances in the prior year consolidated financial statements have been reclassified for comparison purposes to conform to the presentation in the current period consolidated financial statements. During the three-month period ended March 31, 2023, the Company reclassified the carrying amount of Exchanged Notes of $699,781 (see Note 12) that were previously included in the 2022 Notes payable to Unsecured convertible notes.

 

Subsequent Events

 

The Company evaluated all events or transactions through May 22, 2023, the date which these consolidated financial statements were issued. See note 15 for matters deemed to be subsequent events.

 

Going Concern Basis of Accounting

 

As reflected in the consolidated financial statements, the Company has an accumulated deficit as of March 31, 2023, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product and eventually attaining and maintaining profitable operations. In particular, as of March 31, 2023, the Company will be required to raise additional capital, obtain alternative means of financial support, or both, in order to continue to fund operations, and therefore there is substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenses into the foreseeable future for the research, development and commercialization of its current and potential products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may seek to acquire. Finally, some of our product candidates or the materials contained therein (such as the Active Pharmaceutical Ingredients for our AC5® product line), are manufactured from facilities in areas impacted by the outbreak of the COVID-19, which could result in shortages due to ongoing efforts to address the outbreak. Historically, the Company has principally funded operations through debt borrowings, the issuance of convertible debt, and the issuance of units consisting of common stock and warrants. Provisions in the Securities Purchase Agreements that the Company entered into on June 28, 2018 (“2018 SPA”), and July 6, 2022 (“2022 SPA”) restrict the Company’s ability to effect or enter into an agreement to effect any issuance by the Company or its subsidiary of Common Stock or securities convertible, exercisable or exchangeable for Common Stock (or a combination of units thereof) involving a Variable Rate Transaction (as defined in the 2018 SPA and 2022 SPA) including, but not limited to, an equity line of credit or “At-the-Market” financing facility until the institutional investors in the 2018 SPA collectively own less than 20% of the Series F Warrants and the Series G Warrants purchased by them pursuant to the 2018 SPA, respectively and for a period of six months pursuant to the 2022 SPA. Initially, under the 2022 SPA, we were required to complete an uplist to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American by February 15, 2023. On May 15, 2023, the Company secured waivers with all the holders of the 2022 Notes and Second Notes to extend the deadline to complete an Uplisting Transaction to June 15, 2023. See Note 11 for more information regarding the 2022 Convertible Note Offering including the terms of the 2022 Warrants and 2022 Placement Agent Warrants, as well as for more information regarding the Amendment No. 1 to the 2022 SPA, and Amendment No. 2 to the 2022 SPA.

 

The 2021 SPA contains certain restrictions on our ability to conduct subsequent sales of our equity securities (See Note 12). The continued spread of COVID-19 and uncertain market conditions may also limit the Company’s ability to access capital. If the Company is unable to obtain adequate capital, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned activities. These conditions, in the aggregate, raise substantial doubt as to the Company’s ability to continue as a going concern.

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments that might result from this uncertainty.

 

-8-

 

 

 

3. PROPERTY AND EQUIPMENT

 

At March 31, 2023 and September 30, 2022, property and equipment consisted of:

 

   

Estimated

                 
   

Useful Life

(in years)

    March 31,
2023
   

September 30,

2022

 
                         

Furniture and fixtures

    5     $ 9,357     $ 9,357  

Leasehold improvements

  Life of Lease       8,983       8,983  

Computer equipment

    3       14,416       14,416  

Lab equipment

    5       1,000       1,000  
              33,756       33,756  

Less – accumulated depreciation

            32,755       31,712  

Property and equipment, net

          $ 1,001     $ 2,044  

 

For the three months ended March 31, 2023 and 2022, depreciation expense recorded was $380 and $799, respectively. For the six months ended March 31, 2023 and 2022, depreciation expense recorded was $1,043 and $1,598, respectively.

 

 

 

4. INVENTORIES

 

Inventories consist of the following:

 

   

March 31,

   

September 30,

 
   

2022

   

2022

 

Finished Goods

  $ 76,274     $ 9,063  

Goods-in-process

    1,326,110       1,405,785  

Total

  $ 1,402,384     $ 1,414,848  

 

The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not the inventory has a future economic benefit requires estimates by management. To the extent that inventory is expected to expire prior to being sold or used for research and development or used for samples, the Company will write down the value of inventory. In evaluating the net realizable value of the inventory, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors.

 

 

 

5. INSURANCE PREMIUM FINANCING

 

In July 2022, the Company entered into a finance agreement with First Insurance Funding in order to fund a portion of its insurance policies. The amount financed is approximately $354,000 and incurs interest at a rate of 2.99%. The Company is required to make monthly payments of approximately $35,000 through April 2023. The outstanding balance as of March 31, 2023 and September 30, 2022 was approximately $35,000 and $248,000, respectively.

 

 

 

6. STOCK-BASED COMPENSATION

 

2013 Stock Incentive Plan

 

On June 18, 2013, the Company established the 2013 Stock Incentive Plan (the “2013 Plan”). Under the 2013 Plan, as of September 30, 2022, a maximum number of 170,571 shares of the Company’s authorized and available common stock could be issued in the form of options, stock appreciation rights, sales or bonuses of restricted stock, restricted stock units or dividend equivalent rights, and an award may consist of one such security or benefit, or two or more of them in any combination or alternative. The 2013 Plan provides that on the first business day of each fiscal year commencing with fiscal year 2014, the number of shares of our common stock reserved for issuance under the 2013 Plan for all awards except for incentive stock option awards will be subject to increase by an amount equal to the lesser of (A) 15,000 Shares, (B) four (4) percent of the number of shares outstanding on the last day of the immediately preceding fiscal year of the Company, or (C) such lesser number of shares as determined by the Company’s Board of Directors (the “Board”). The exercise price of each option shall be the fair value as determined in good faith by the Board at the time each option is granted. On October 1, 2022, the aggregate number of authorized shares under the Plan was further increased by 15,000 shares to a total of 185,571 shares.

 

The exercise price of each option is equal to the closing price of a share of the Company’s Common Stock on the date of grant.

 

Share-Based Awards

 

During the six months ended March 31, 2023, the Company awarded 20,875 options to employees and directors and 3,625 options to consultants to purchase shares of Common Stock under the 2013 Plan.

 

Share-based compensation expense for awards granted during the six months ended March 31, 2023 was based on the grant date fair value estimated using the Black-Scholes Model.

 

-9-

 

 

Common Stock Options

 

Stock compensation activity under the 2013 Plan for the six months ended March 31, 2023 follows:

 

   

Option

Shares

Outstanding

   

Weighted

Average

Exercise

Price

   

Weighted

Average

Remaining

Contractual

Term

(years)

   

Aggregate

Intrinsic

Value

 

Outstanding at September 30, 2022

    98,626     $ 52.00       1.36     $ 16,900  

Awarded

    24,500     $ 8.00                  

Forfeited/Cancelled

    (18,801

)

  $ 70.00                  

Outstanding at March 31, 2023

    104,325     $ 39.00       5.95       104,300  

Vested at March 31, 2023

    74,000     $ 50.00       4.89       74,000  

Vested and expected to vest at March 31, 2023

    104,325     $ 39.00       5.95       104,300  

 

As of March 31, 2023, 50,667 shares are available for future grants under the 2013 Plan.

 

Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022 resulting from options awarded to the Company’s employees, directors and consultants was approximately $68,000 and $145,000, respectively. Of this amount, during the three months ended March 31, 2023 and 2022, $34,000 and $41,000, respectively, were recorded as research and development expense, and $34,000 and $104,000, respectively were recorded as general and administrative expense in the Company’s Consolidated Statements of Operations. Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the six months ended March 31, 2023 and 2022 resulting from options awarded to the Company’s employees, directors and consultants was approximately $170,000 and $287,000, respectively. Of this amount, during the six months ended March 31, 2023 and 2022, $48,000 and $94,000, respectively, were recorded as research and development expense, and $122,000 and $193,000, respectively were recorded as general and administrative expense in the Company’s Consolidated Statements of Operations.

 

During the six months ended March 31, 2023 and 2022, no options awarded were exercised.

 

As of March 31, 2023, there is approximately $245,000 of unrecognized compensation expense related to unvested stock-based compensation arrangements granted under the 2013 Plan. That cost is expected to be recognized over a weighted average period of 2.40 years.

 

Restricted Stock

 

Restricted stock activity under the 2013 Plan for the three months ended March 31, 2023 and 2022, in shares, follows:

 

   

Three months Ended

 
   

March 31, 2023

   

March 31, 2022

 

Non Vested at December 31, 2022 and 2021

    250       1,875  

Vested

    (250 )    

(625

)

Non Vested at March 31, 2023 and 2022

    -       1,250  

 

The weighted grant date fair value average of the restricted stock for the three months ended March 31, 2023 and 2022 follows:

 

   

Three months Ended

 
   

March 31, 2023

   

March 31, 2022

 

Non Vested at December 31, 2022 and 2021

  $ 18.00     $ 20.00  

Vested

    (18.00 )    

(20.00

)

Non Vested at March 31, 2023 and 2022

  $ -     $ 20.00  

 

Restricted stock activity under the 2013 Plan for the six months ended March 31, 2023 and 2022, in shares, follows:

 

   

Six months Ended

 
   

March 31, 2023

   

March 31, 2022

 

Non Vested at September 30, 2022 and 2021

    250       2,250  

Vested

    (250

)

    (1,000

)

Non Vested at March 31, 2023 and 2022

    -       1,250  

 

The weighted grant date fair value average of the restricted stock for the six months ended March 31, 2023 and 2022 follows:

 

   

Six months Ended

 
   

March 31, 2023

   

March 31, 2022

 

Non Vested at September 30, 2022 and 2021

  $ 18.00     $ 20.00  

Vested

    (18.00

)

    (20.00

)

Non Vested at March 31, 2023 and 2022

  $ -     $ 20.00  

 

For the three months ended March 31, 2023 and 2022, compensation expense recorded for the restricted stock awards was approximately $1,000 and $10,000, respectively. For the six months ended March 31, 2023 and 2022, compensation expense recorded for the restricted stock awards was approximately $3,000 and $20,000, respectively.

 

-10-

 

 

 

7. REGISTERED DIRECT OFFERINGS

 

On September 30, 2016, the Company filed a registration statement with the SEC utilizing a “shelf” registration process, which was subsequently declared effective by the SEC on October 20, 2016 (such registration statement, the “Shelf Registration Statement”). Under the Shelf Registration Statement, the Company may offer and sell any combination of its Common Stock, warrants, debt securities, subscription rights, and/or units comprised of the foregoing to raise up to $50,000,000 in gross proceeds.

 

On February 20, 2017, the Company entered into a Securities Purchase Agreement (the “2017 SPA”) with six accredited investors (collectively, the “2017 Investors”) providing for the issuance and sale by the Company to the 2017 Investors of an aggregate of 50,833 units at a purchase price of $120.00per unit in a registered offering (the “2017 Financing”). The securities comprising the units sold in the 2017 Financing were issued under the Shelf Registration Statement, and consisted of a share of Common Stock, a warrant equal to 55% of the shares of Common Stock at an exercise price of $150.00 per share (“Series F Warrant”) at any time prior to the fifth anniversary of the issuance date of the Series F Warrant subject to certain restrictions on exercise (the “2017 Warrants”) and the shares issuable upon exercise of the 2017 Warrants (the “2017 Warrant Shares”).

 

On June 28, 2018, the Company entered into a Securities Purchase Agreement (“2018 SPA”) with eight accredited investors (collectively, the “2018 Investors”) providing for the issuance and sale by the Company to the 2018 Investors of an aggregate of 45,350 units at a purchase price of $100.00 per unit in a registered offering (“2018 Financing”). The securities comprising the units sold in the 2018 Financing were issued under the Shelf Registration Statement, and consisted of a share of Common Stock, a warrant to purchase up to a number of shares of the Company’s Common Stock equal to 75% of the shares of Common Stock at an exercise price of $140.00 per share (“Series G Warrant”) at any time prior to the fifth anniversary of the issuance date of the Series G Warrant subject to certain restrictions on exercise (the “2018 Warrants”) and the shares issuable upon exercise of the 2018 Warrants (the “2018 Warrant Shares”).

 

On May 12, 2019, the Company entered into a Securities Purchase Agreement (“2019 SPA”) with five accredited investors (collectively, the “2019 Investors”) providing for the issuance and sale by the Company to the 2019 Investors of an aggregate of 43,077 units at a purchase price of $65.00 per unit in a registered offering (“2019 Financing"). The securities comprising the units sold in the 2019 Financing were issued under the Shelf Registration Statement, and consisted of a share of Common Stock, a warrant to purchase one share of Common Stock at an exercise price of $80.00 per share (“Series H Warrant”) at any time prior to the fifth anniversary of the issuance date of the Series H Warrant subject to certain restrictions on exercise (the “2019 Warrants”) and the shares issuable upon exercise of the 2019 Warrants (the “2019 Warrant Shares”).

 

On March 10, 2023, the Company entered into exchange agreements (the “Exchange Agreements”) with each holder (the “Warrantholders”) of the Company’s outstanding Series G Warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at an exercise price of $140.00 per share (the “Series G Warrants”) and the Company’s outstanding Series H Warrants to purchase shares of Common Stock at an exercise price of $80.00 per share (the “Series H Warrants” and, together with the Series G Warrants, the “Warrants”). Pursuant to the Exchange Agreements, the Warrantholders exchanged 34,013 Series G Warrants for 3,402 shares of Common Stock and 43,077 Series H Warrants for 8,617 shares of Common Stock. All 27,958 remaining Series F Warrants expired during the fiscal year ended September 30, 2022.

 

8. Derivative Liabilities

 

The Company accounted for the Series F Warrants, Series G Warrants and the Series H Warrants in accordance with ASC 815-10. Since the Company was required to purchase its Series F Warrants, Series G Warrants and Series H Warrants for an amount of cash equal to $36.00, $22.00 and $10.66, respectively, for each share of Common Stock ("Minimum") they are recorded as liabilities at the greater of the Minimum or fair value. They are marked to market each reporting period through the Consolidated Statement of Operations.

 

On the respective closing dates of June 28, 2018 and May 12, 2019, respectively, the derivative liabilities related to the Series G Warrants and Series H Warrants were recorded at an aggregate fair value of $1,628,113. Given that the fair value of the derivative liabilities was less than the net proceeds, the remaining proceeds were allocated to Common Stock and additional paid-in-capital.

 

On March 10, 2023, Arch Therapeutics, Inc. entered into exchange agreements (the “Exchange Agreements”) with each holder (the “Warrantholders”) of the Company’s outstanding Series G Warrants to purchase shares of the Company’s common stock, par value $0.001 per share at an exercise price of $140.00 per share and the Company’s outstanding Series H Warrants to purchase shares of Common Stock at an exercise price of $80.00 per share. Pursuant to the Exchange Agreements, the Warrantholders exchanged 34,013 Series G Warrants for 3,402 shares of Common Stock and 43,077 Series H Warrants for 8,617 shares of Common Stock.

 

During the three months ended March 31, 2023, $1,158,197 was recorded to gain on extinguishment of derivative liability for the exchange of the Series G warrants and Series H warrants and $49,278 was recorded as part of shareholder’s deficit. During the three months ended March 31, 2023 and 2022, $0 and $1,000,000, respectively was recorded to decrease the fair value of derivative liability related to the Series F warrants.

 

Fair Value Measurements Using Significant Unobservable Inputs Six Months Ended March 31, 2023

               

(Level 3)

 

Series G

   

Series H

 
                 

Beginning balance at September 30, 2022

  $ 748,275     $ 459,200  

Exchange of warrants into common stock

    (13,948

)

    (35,330

)

Extinguishment of derivative liabilities     (734,327 )     (423,870 )

Ending balance at March 31, 2023

  $     $  

 

Fair Value Measurements Using Significant Unobservable Inputs - Six Months Ended March 31, 2022

                       

(Level 3)

 

Series F

   

Series G

   

Series H

 
                         

Beginning balance at September 30, 2021

  $ 1,000,000     $ 748,275     $ 459,200  

Issuances

                 

Adjustments to estimated fair value

                 
Expiration of derivative liability     (1,000,000 )            

Ending balance at March 31, 2022

  $     $ 748,275     $ 459,200  

 

-11-

 

 

The derivative liabilities as of March 10, 2023 and September 30, 2022 are valued at the greater of their minimum value or by using the Black Scholes Model with the following assumptions.

 

As of March 10, 2023, the derivative liabilities are recorded at their minimum value.

 

   

Series G

   

Series H

 

Closing price per share of Common Stock

  $ 4.10     $ 4.10  

Exercise price per share

  $ 140.00     $ 80.00  

Expected volatility

    179.41

%

    141.03

%

Risk-free interest rate

    4.91

%

    4.75

%

Dividend yield

    -       -  

Remaining expected term of underlying securities (years)

    0.24       1.31  

 

 

As of September 30, 2022, the derivative liabilities are recorded at their minimum value.

 

   

Series G

   

Series H

 

Closing price per share of Common Stock

  $ 3.84     $ 3.84  

Exercise price per share

  $ 140.00     $ 80.00  

Expected volatility

    132.97

%

    122.50

%

Risk-free interest rate

    4.05

%

    4.14

%

Dividend yield

           

Remaining expected term of underlying securities (years)

    0.69       1.57  

 

 

 

9. OCTOBER 2019 REGISTERED DIRECT OFFERING

 

On October 16, 2019, the Company entered into a Securities Purchase Agreement (the October 2019 SPA) with seven accredited investors (collectively, the “October 2019 Investors”) providing for the issuance and sale by the Company to the 2019 Investors of an aggregate of 71,429 units at a purchase price of $35.00 per unit in a registered offering (“October 2019 Financing”). The securities comprising the units sold in the October 2019 Financing were issued under the Shelf Registration Statement, and consisted of a share of Common Stock, a warrant to purchase one share of Common Stock at an exercise price of $44.00 per share (“Series I Warrant”) at any time prior to the fifth anniversary of the issuance date of the Series I Warrant subject to certain restrictions on exercise and the shares issuable upon exercise of the Series I Warrants (collectively, the “October 2019 Warrant Shares”). As of October 18, 2019, the Company recorded the 71,429 shares as Common Stock. Pursuant to the Engagement Agreement (as defined below), the Company also agreed to issue to the Placement Agent, or its designees, warrants to purchase up to 5,358 shares (the “Placement Agent Warrants”). The 2019 Placement Agent Warrants have substantially the same terms as the Series I Warrants, except that the exercise price of the Placement Agent Warrants is $43.75 per share and the term of the Placement Agent Warrants is five years.

 

The gross proceeds to the Company from the October 2019 Financing, which were received as of October 18, 2019, were approximately $2.5 million before deducting financing costs of approximately $333,000 which includes approximately $158,000 of placement fees. The number of shares of the Company’s Common Stock into which each of the Series I Warrants is exercisable and the exercise price therefore are subject to adjustment, as set forth in the Series I Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise).

 

The Company engaged H.C. Wainwright as its exclusive institutional investor placement agent (the “Placement Agent”) in connection with the October 2019 SPA pursuant to an engagement agreement dated as of October 10, 2019 (the “2019 Engagement Agreement”). In consideration for the services provided by the Placement Agent, the Placement Agent was entitled to receive cash fees ranging from 6.0% to 8.2% of the gross proceeds received by the Company, as well as reimbursement for all reasonable expenses incurred by it in connection with its engagement. The Company received gross proceeds of approximately $2.5 million in the aggregate, resulting in a fee of approximately $158,000.

 

During the three and six months ended March 31, 2023 and 2022, no Series I Warrants or Placement Agent Warrants were exercised. As of March 31, 2023, up to 71,429 and 5,358 shares may be acquired upon the exercise of the Series I Warrants and Placement Agent Warrants, respectively.

 

-12-

 

 

Common Stock

 

On October 18, 2019, the Closing Date of the October 2019 Financing, the Company issued 71,429 shares of Common Stock.

 

Equity Value of Warrants

 

The Company accounted for the Series I Warrants and the Placement Agent Warrants relating to the aforementioned October 2019 Financing in accordance with ASC 815-40. Because the Series I Warrants and the Placement Agent Warrants are indexed to the Company’s Common Stock, they are classified within stockholders’ deficit in the accompanying consolidated financial statements.

 

 

10. 2021 REGISTERED DIRECT OFFERING

 

On February 11, 2021, the Company entered into a Securities Purchase Agreement (the “2021 SPA”) with certain institutional and accredited investors (collectively, “2021 Investors”) providing for the issuance and sale by the Company to the 2021 Investors of an aggregate of 215,625 shares (the “Shares”) of the Company’s Common Stock, and warrants (the “Series K Warrants”) to purchase an aggregate of 161,719 shares (the “Warrant Shares”) of Common Stock, at a combined offering price of $32.00 per share (the “2021 Financing”). The Series K Warrants have an exercise price of $34.00 per share and are exercisable for a period of 5.5 years. The aggregate gross proceeds for the sale of the Shares and Series K Warrants were approximately $6.9 million, before deducting the Placement Agent’s fees and expenses and other offering expenses payable by the Company, of approximately $700,000. Pursuant to an engagement agreement dated as of February 8, 2021 (the “2021 Engagement Agreement”), by and between the Company and the Placement Agent, the Company agreed to pay the Placement Agent cash fees equal to (i) 7.5% of the gross proceeds received by the Company from certain investors in the 2021 Financing, and (ii) 6.0% of the gross proceeds received by the Company from certain investors that had pre-existing relationships with the Company. In addition, the Placement Agent received a one-time non-accountable expense fee of $10,000, up to $50,000 for fees and expenses of legal counsel and other out-of-pocket expenses and $10,000 for clearing expenses. Pursuant to the 2021 Engagement Agreement, the Company also agreed to issue to the Placement Agent, or its designees, warrants to purchase up to 7.5% of the aggregate number of Shares sold to the 2021 Investors, or warrants to purchase up to 16,172 shares (the “2021 Placement Agent Warrants”) of the Company’s Common Stock. The 2021 Placement Agent 2 Warrants have substantially the same terms as the Series K Warrants, except that the exercise price of the 2021 Placement Agent Warrants is $40.00 per share. The 2021 Engagement Agreement contained indemnity and other customary provisions for transactions of this nature.

 

The 2021 SPA contained certain restrictions on the Company’s ability to conduct subsequent sales of the Company’s equity securities. In particular, we were prohibited from entering into or effecting a Variable Rate Transaction (as defined in the 2021 SPA) until February 11, 2022; provided, however, the Company may enter into and effect an at-the-market offering facility with the Placement Agent.

 

The number of shares of the Company’s Common Stock into which each of the Series K Warrants is exercisable and the exercise price therefore are subject to adjustment, as set forth in the Series K Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise).

 

During the three and six months ended March 31, 2023, no Series K Warrants or Placement Agent 2 Warrants were exercised. As of March 31, 2023, up to 161,719 and 16,172 shares may be acquired upon the exercise of the Series K Warrants and Placement Agent Warrants, respectively.

 

Common Stock

 

On February 17, 2021, the Closing Date of the 2021 Financing, the Company issued 215,625 shares of Common Stock.

 

Equity Value of Warrants

 

The Company accounted for the Series K Warrants and the Placement Agent 2 Warrants relating to the aforementioned February 2021 Registered Direct Offering in accordance with ASC 815-40, Derivatives and Hedging. Because the Series K Warrants and the Placement Agent 2 Warrants are indexed to the Company’s stock, they are classified within stockholders’ deficit in the accompanying consolidated financial statements.

 

-13-

 

 

 

11. 2022 CONVERTIBLE NOTE OFFERING AND SECOND NOTES OFFERING

 

On July 7, 2022, the Company announced that it had entered into a Securities Purchase Agreement (the “2022 SPA”) with certain institutional and accredited individual investors (collectively, the “2022 Investors”) providing for the issuance and sale by the Company to the 2022 Investors of (i) Senior Secured Convertible Promissory Notes (each a “2022 Note” and collectively, the “2022 Notes”) in the aggregate principal amount of $4.23 million, which includes an aggregate $0.705 million original issue discount in respect of the 2022 Notes; (ii) warrants (the “2022 Warrants”), to purchase an aggregate of 425,554 shares (the “2022 Warrant Shares”) of Common Stock; and (iii) 63,833 shares of Common Stock (the “2022 Inducement Shares”) equal to 15% of the principal amount of the 2022 Notes divided by the closing price of the Common Stock immediately prior to the Closing Date (as defined below). The 2022 Notes, 2022 Warrants and 2022 Inducement Shares were issued as part of a convertible note offering authorized by the Company’s board of directors (the “2022 Convertible Note Offering”). The aggregate gross proceeds for the sale of the 2022 Notes, 2022 Warrants and 2022 Inducement Shares was approximately $3.5 million, before deducting debt issuance costs of $775,000 consisting of fair value of the placement agent’s warrants of approximately $220,000 and other estimated fees and offering expenses payable by the Company of approximately $555,000. The closing of the sales of these securities under the 2022 SPA occurred on July 6, 2022 (the “2022 Closing Date”).

 

On January 18, 2023, the Company entered into Amendment No. 1 to the 2022 SPA (the “Amendment” and, together with the 2022 SPA, the “Amended 2022 SPA”), with certain Investors in connection with the Second Closing of the 2022 Convertible Note Offering for the issuance and sale by the Company to such Investors of an aggregate of (i) Unsecured Convertible Promissory Notes (each a “Second Note” and collectively, the “Second Notes”) in the aggregate principal amount of $636,000, which includes an aggregate $106,000 original issue discount in respect of the Second Notes; (ii) warrants (the “Second Warrants”) to purchase an aggregate of 127,968 shares (the “Second Warrant Shares”) of Common Stock; and (iii) 9,598 shares of Common Stock (the “Second Inducement Shares”). The aggregate gross proceeds for the sale of the Second Notes, Second Warrants and Second Inducement Shares was approximately $530,000, before deducting the placement agent’s fees and other estimated fees and offering expenses payable by the Company of approximately $15,000. The second closing of the sales of these securities under the Amended 2022 SPA occurred on January 18, 2023 (the “Second Closing Date”).

 

The 2022 Notes and the Second Notes bear interest on the unpaid principal balance at a rate equal to ten percent (10%) (computed on the basis of the actual number of days elapsed in a 360-day year) per annum accruing from the Closing Date until the 2022 Notes and Second Notes become due and payable at maturity or upon their conversion, acceleration or by prepayment, and may become due and payable upon the occurrence of an event of default under the 2022 Notes and Second Notes. Any amount of principal or interest on the 2022 Notes and Second Notes which is not paid when due shall bear interest at the rate of the lesser of (i) eighteen percent (18%) per annum or (ii) the maximum amount allowed by law from the due date thereof until payment in full.

 

The 2022 Notes and the Second Notes are convertible into shares of Common Stock at the option of each holder of the 2022 Notes and the Second Notes from the date of issuance at $9.14 (the “Conversion Price”) through the later of (i) January 6, 2024 (the “Maturity Date”) or (ii) the date of payment of the Default Amount (as defined in the 2022 Notes); provided, however, certain 2022 Notes and Second Notes include a provision preventing such conversion if, as a result, the holder, together with its affiliates and any other persons whose beneficial ownership of Common Stock would be aggregated with the holder’s, would be deemed to beneficially own more than 4.99% of the Common Stock (as applicable, the “Ownership Limitation”) immediately after giving effect to the Conversion; and provided further, the holder, upon notice to us, may increase or decrease the Ownership Limitation; (i) the Ownership Limitation may only be increased to a maximum of 9.99% of the Common Stock; and (ii) any increase in the Ownership Limitation will not become effective until the 61st day after delivery of such waiver notice. The Conversion Price is subject to adjustment as set forth in the 2022 Notes and Second Notes.

 

The 2022 Notes and Second Notes contain customary events of default, which include, among other things, (i) our failure to pay when due any principal or interest payment under the 2022 Notes and Second Notes; (ii) our insolvency; (iii) delisting of our Common Stock; (iv) our breach of any material covenant or other material term or condition under the 2022 Notes and Second Notes; and (v) our breach of any representations or warranties under the 2022 Notes and Second Notes which cannot be cured within five (5) days. Further, events of default under the 2022 Notes and Second Notes also include (i) the unavailability of Rule 144 on or after January 6, 2023; (ii) our failure to deliver the shares of Common Stock to the 2022 Notes and/or Second Notes holder upon exercise by such holder of its conversion rights under the 2022 Note; (iii) our loss of the “bid” price for its Common Stock and/or a market and such loss is not cured during the specified cure periods; and (iv) our failure to complete an uplisting of our Common Stock to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American by June 15, 2023 (as amended) (an “Uplist Transaction”).

 

The 2022 Warrants and the Second Warrants (i) have an exercise price of $9.94 per share; (ii) have a term of exercise equal to 5 years after their issuance date; (iii) became exercisable immediately after their issuance; and (iv) have a provision preventing the exercisability of such 2022 Warrants and Second Warrants if, as a result of the exercise of the 2022 Warrants and Second Warrants, the holder, together with its affiliates and any other persons whose beneficial ownership of our Common Stock would be aggregated with the holder’s, would be deemed to beneficially own more than the Ownership Limitation. The holder, upon notice to us, may increase or decrease the Ownership Limitation; provided that (i) the Ownership Limitation may only be increased to a maximum of 9.99% of our Common Stock; and (ii) any increase in the Ownership Limitation will not become effective until the 61st day after delivery of such waiver notice. The number of shares of Common Stock into which each of the 2022 Warrants and Second Warrants is exercisable and the exercise price therefor are subject to adjustment as set forth in the 2022 Warrants and Second Warrants, including standard antidilution provisions, and adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise). In the event of a Fundamental Transaction (as defined in the 2022 Warrants and Second Warrants) holders of the 2022 Warrants and Second Warrants would be entitled to receive alternate consideration in connection with such Fundamental Transaction, but only to the extent that holders of our Common Stock were entitled to receive the same. Moreover, as long as the 2022 Notes and Second Notes and 2022 Warrants and Second Warrants remaining outstanding, upon the issuance of any security in connection with any potential future financing activity on terms more favorable than the existing terms, the Company has an obligation to notify the holders of the 2022 Notes and Second Notes and 2022 Warrants and Second Warrants of such more favorable terms and to use best efforts to effect such terms in the 2022 Notes and Second Notes and 2022 Warrants and Second Warrants. Finally, because of the Company’s net loss position, the shares underlying the 2022 Notes and Second Notes on an as converted basis are excluded from the calculation of basic and fully diluted earnings per share. Similarly, because of the Company’s net loss position, there was no impact on the calculation of basic and fully diluted earnings per share related to the classification of the 2022 Warrants and Second Warrants as participating securities.

 

-14-

 

The Company retained a placement agent in connection with the private placement of $2.4 million of the 2022 Notes to the institutional investors. The Company paid the 2022 Placement Agent 10% of the gross proceeds received from certain institutional investors, or $240,000 and we also reimbursed the 2022 Placement Agent approximately $58,000 for non-accountable banking fees, legal fees and other expenses. In addition, we issued 2022 Placement Agent Warrants to purchase an aggregate of 31,510 shares of Common Stock. An additional $1.1 million was raised in connection with the placement of the private placement notes, which included certain accredited investors some of which were Board members and executive officers of the Company. Board member, Laurence Hicks, and executive officers, Terrence W. Norchi and Michael S. Abrams, invested in the 2022 Notes. The investment made in the 2022 Notes made by the Board member and executive officers totaled $80,000.

 

The Company’s agreement with the 2022 Placement Agent was still effective at the time of the private placement of $0.5 million of the Second Notes to certain institutional investors. The Company owes the 2022 Placement Agent 10% of the gross proceeds received from certain institutional investors, or $50,000, such amount was deferred until the Company completes an additional financing with gross proceeds of at least $1 million. In addition, we issued or are required to issue 2022 Placement Agent Warrants to purchase an aggregate of 6,565 shares of Common Stock.

 

In addition, as a part of the 2022 Convertible Note Offering, certain holders of the Company’s 10% Series 2 Convertible Notes agreed to exchange their Series 2 Notes for promissory notes of the Company on substantially similar terms to those of the 2022 Notes (the “Exchanged Notes”). The Exchanged Notes are convertible into 76,563 shares of Common Stock at a conversion price of $9.14. The holders of the Exchanged Notes did not receive warrants or inducement shares. In connection with the issuance of the Exchanged Notes, the holders of the Series 2 Notes that participated in the exchange entered into a subordination agreement on July 6, 2022 (the “Closing Date”) to subordinate their rights in respect of the Exchanged Notes to the rights of the Investors in respect of the 2022 Notes. As of July 7, 2022, approximately $600,000 of the Series 2 Notes and accrued interest of approximately $100,000 were included in the exchange.

 

Further, in connection with the 2022 Convertible Note Offering, we initially were required to complete an Uplist Transaction by February 15, 2023 under the terms of the 2022 Notes. If we are unable to complete or secure an extension to the Uplist Transaction deadline, then the 2022 Notes and Second Notes will become immediately due and payable and we will be obligated to pay to each holder of the 2022 Notes and Second Notes an amount equal to 125%, multiplied by the sum of the outstanding principal amount of the 2022 Notes and Second Notes plus any accrued and unpaid interest on the unpaid principal amount of the 2022 Notes and Second Notes to the date of payment, plus any default interest and any other amounts owed to the holder, payable in cash or shares of Common Stock. The Company has secured waivers from all of the holders of the 2022 Notes and Second Notes to extend the deadline to complete an uplist from (i) February 15, 2023 to March 15, 2023, (ii) March 15, 2023 to April 15, 2023, (iii) April 15, 2023 to May 15, 2023 and (iv) effective May 15, 2023 to June 15, 2023. No consideration was paid by the Company in connection with any of the Uplist Transaction deadline extensions.

 

On March 10, 2023, the Company entered into an amendment (“Amendment No. 2 to the First Notes”) with each of the holders of the Company’s outstanding 2022 Notes issued in connection with a private placement financing the Company completed on July 6, 2022 (the “First Closing”). On March 10, 2023, the Company also entered into an amendment (“Amendment No. 2 to the Second Notes” and, together with Amendment No. 2 to the First Notes, “Amendment No. 2 to the 2022 Notes”) with each Second Notes issued in connection with a private placement financing the Company completed on January 18, 2023.

 

Under Amendment No. 2 to the 2022 Notes and Second Notes, the following amendments to the 2022 Notes will be effective at the moment in time immediately preceding the consummation of the offering in connection with the uplist of the Common Stock to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American (the “Uplist Transaction”). If a holder of the 2022 Notes and/or the Second Notes elects to participate in the Uplist Transaction (each, a “Participating Holder”) for an amount equal to no less than 50% of the Participating Holder’s original investment amount in the 2022 Convertible Note Offering, such holder will be entitled to repayment of the principal amount of their 2020 Notes and/or Second Notes upon closing of the Uplist Transaction. In addition, the Company will issue to each Participating Holder a new convertible promissory note equal to the product of 2.4 and the sum of any prepayment premiums and total interest payable on such Participating Holder’s 2022 Notes and/or Second Notes (the “2023 Notes”). The 2023 Notes will have a maturity date of July 6, 2024 and will be on substantially the same terms as the Second Notes. For non-Participating Holders (each, a “Non-Participating Holder”), the maturity date of the 2022 Notes and/or Second Notes held by such Non-Participating Holder will be extended to July 6, 2024. Further, each Non-Participating Holder will waive their right to demand repayment of any portion of the outstanding balance of such holder’s 2022 Notes and/or upon an Uplist Transaction. Notwithstanding the foregoing, if the registration statement filed in connection with the Uplist Transaction is not declared effective by 11:59 P.M. (EST) on June 15, 2023 (the “Amendment No. 2 Termination Date”), Amendment No. 2 to the 2022 Notes will automatically terminate and shall be of no further force or effect without any further action by the Company or the Requisite Holders, provided, that the Amendment No. 2 Termination Date may be extended by the written approval of the Company and holders of the 2022 Notes and Second Notes which purchased at least 50% plus $1.00 of the 2022 Notes and Second Notes based on the initial principal amounts thereunder (the “Requisite Holders”).

 

During the three months ended March 31, 2023, the Company recorded interest expense on the 2022 Notes and the Second Notes of approximately $610,000 consisting of accrued interest of approximately $136,000 and accretion of original issue discount debt discount and issuance costs of approximately $474,000. During the six months ended March 31, 2023, the Company recorded interest expense on the 2022 Notes and the Second Notes of approximately $1,110,000 consisting of accrued interest of approximately $263,000 and accretion of original issue discount debt discount and issuance costs of approximately $847,000.

 

-15-

 

Allocation of Proceeds

 

The Company accounted for the 2022 Notes and Second Notes, the 2022 Warrants and the Second Warrants, the 2022 Inducement Shares and Second Inducement Shares relating to the aforementioned 2022 Notes and Second Notes in accordance with ASC 470-20-25-2 “Debt” which states that the allocation of the proceeds from the financing shall be based on the relative fair values of the securities issued at the time of the issuance. The 2022 Inducement Shares and the 2022 Warrants, which are indexed to the Company’s stock, are classified within stockholders’ equity (deficit) in the accompanying consolidated financial statements. The allocated value of the 2022 Inducement Shares and the 2022 Warrants are $314,523 and $1,470,133, respectively. The allocated value of the Second Inducement Shares and the Second Warrants are $25,840 and $256,439, respectively. The allocated value of the 2022 Notes of $1,740,344 are allocated as short-term liabilities in the accompanying consolidated financial statements. The allocated value of the Second Notes of $247,721 are allocated as short-term liabilities in the accompanying consolidated financial statements The fair value of the 2022 Placement Agent Warrants and the Second Placement Agent Warrants of $219,894 and $28,093, respectively, are being accounted for as debt issuance costs and are classified within stockholders’ equity (deficit) in the accompanying consolidated financial statements. As of March 31, 2023 and September 30, 2022, the net carrying amount of the 2022 Notes was $2,454,683 and $1,662,492, respectively, with unamortized debt discount and issuance costs of $1,775,317 and $2,567,508, respectively. As of March 31, 2023, the Company reclassified the carrying amount of the Exchanged Notes of $699,781 (see Note 12) that were previously included in 2022 Notes payable to Unsecured convertible notes. After the reclassification, the Unsecured convertible notes included both the Second Notes and the Exchanged Notes. In addition, as of March 31, 2023, the net carrying amount of the Second Notes was $281,536 with unamortized debt discount and issuance costs of $354,464 and are also included in Unsecured convertible notes.

 

The 2022 Warrants and the 2022 Placement Agent Warrants were valued as of July 6, 2022 using the Black Scholes Model with the following assumptions:

 

   

2022 Warrants

   

2022 Placement

Agent Warrants

 

Closing price per share of Common Stock

  $ 9.98     $ 9.98  

Exercise price per share

  $ 9.94     $ 10.06  

Expected volatility

    88.44

%

    88.44

%

Risk-free interest rate

    2.96

%

    2.96

%

Dividend yield

           

Remaining expected term of underlying securities (years)

    5.0       5.0  

 

-16-

 

 

The Second Warrants and the Second Placement Agent Warrants were valued as of January 18, 2023 using the Black Scholes Model with the following assumptions:

 

   

Second Warrants

   

Second Placement

Agent Warrants

 

Closing price per share of Common Stock

  $ 5.76     $ 5.76  

Exercise price per share

  $ 9.94     $ 10.06  

Expected volatility

    111.31

%

    111.31

%

Risk-free interest rate

    3.43

%

    3.43

%

Dividend yield

           

Remaining expected term of underlying securities (years)

    5.0       5.0  

 

 

 

12. SERIES CONVERTIBLE NOTES

 

On June 4, 2020 and November 6, 2020, the Company issued unsecured 10% Series 1 Convertible Notes (“Series 1 Notes”) and Series 2 Convertible Notes (“Series 2 Notes”, and collectively with the Series 1 Notes, the “Series Convertible Notes”) in the aggregate principal amount of $550,000 and $1,050,000, respectively. The maturity dates of the Series 1 Notes and Series 2 Notes are June 30, 2023 and November 30, 2023, respectively. The Series Convertible Notes provide, among other things, for (i) a term of approximately three years; (ii) the Company’s ability to prepay the Series Convertible Notes, in whole or in part, at any time; (iii) the automatic conversion of the Series Convertible Notes upon a Change of Control (all capitalized terms not otherwise defined to have the meaning ascribed to such terms of the Series Convertible Notes) into shares of the Company’s Common Stock, at a per share price of $54.00 and $50.00 (the “Conversion Price”) for the Series 1 Notes and Series 2 Notes, respectively; (iv) the ability of the holders of the Series Convertible Notes (each a “Holder”, and together, the “Holders”) to convert the principal of the Series Convertible Notes, along with accrued interest, in whole or in part, into shares of Common Stock at the respective Conversion Price; (v) the Company’s ability to convert all Note Obligations outstanding upon a Qualified Equity Financing into shares of Common Stock at the respective Conversion Price; (vi) the Company’s ability to convert the principal of the Series Convertible Notes, along with accrued interest, in whole or in part, into shares of Common Stock at the respective Conversion Price in the event the volume weighted average price (“VWAP”) of the Common Stock equals or exceeds $64.00 per share for at least fifteen consecutive Trading Days; (vii) the Company’s ability to convert all outstanding Note Obligations into shares of Common Stock at the respective Conversion Price (an “In Kind Note Repayment”) in lieu of repaying the Note Obligations outstanding on the Maturity Date, provided, however, that in the case of an In-Kind Note Repayment, the outstanding Note Obligations will be calculated by increasing by thirty-five percent the aggregate sum of the unpaid Principal Amount held by each Holder and the accrued interest at a rate of ten percent per annum, subject to, with respect to any portion of the Principal Amount that is converted or prepaid before the twelve month anniversary of the Issuance Date, a minimum interest payment equal to ten percent of the amount that is converted or prepaid. As consideration for agreeing to subordinate to the 2022 Notes, the premium applicable in connection with an In-Kind Note Repayment at maturity was increased from thirty-five percent to sixty percent.

 

Beginning June 22, 2015 and through June 30, 2015, the Company entered into a series of substantially similar subscription agreements with 20 accredited investors providing for the issuance and sale by the Company to the 2015 Investors, in a private placement, of an aggregate of 71,954 Units at a purchase price of $44.00 per Unit. Each Unit consisted of a share of Common Stock and a Series D Warrant to purchase a share of Common Stock at an exercise price of $50.00 per share at any time prior to the fifth anniversary of the issuance date of the Series D Warrant and the shares issuable upon exercise of the Series D Warrants.

 

On June 3, 2020, the Company entered into an agreement (the “Agreement”) with the holders of a majority (the “Majority Holders”) of the outstanding warrants classified as “Series D Warrants”, resulting in approximately $850,000 of proceeds as a result of the full exercise of all Series D Warrants. Under the terms of the Agreement, in exchange for fully exercising their remaining Series D Warrants for 23,636 shares of Common Stock on June 4, 2020, the Majority Holders were issued warrants to purchase 17,727 shares of Common Stock at an exercise price of $50.00 over a 1-year term (“Series J Warrants”). On November 6, 2020, as consideration for an investment in the Series Convertible Notes, the Company entered into an amendment to the Series J Warrants with a holder of a Series J Warrant exercisable for up to 16,875 shares of Common Stock, to extend the term of the Series J Warrant from one year to thirty months.

 

On June 22, 2020, the Company entered into a Series J Warrant Issuance Agreement (the “Keyes Sulat Agreement”) with the Keyes Sulat Revocable Trust (the “Trust”), also a holder of outstanding Series D Warrants, resulting in approximately $82,000 of proceeds as a result of the full exercise of the Trust’s Series D Warrants. Under the terms of the Keyes Sulat Agreement, in exchange for fully exercising the Trust’s remaining Series D Warrants for 2,273 shares of Common Stock on June 22, 2020, the Trust was issued Series J Warrants to purchase 1,705 shares of Common Stock at an exercise price of $50.00 over a one-year term. James R. Sulat, a former member of the Board, is a co-trustee of the Trust, of which members of Mr. Sulat’s immediate family are beneficiaries. Mr. Sulat disclosed his interest in the Trust to the Board prior to its approval of the transaction and abstained from voting on the transaction.

 

As described in Note 11 above, as a part of the 2022 Convertible Note Offering, certain holders of the Series 2 Notes agreed to exchange Series 2 Notes with an aggregate principal amount of $600,000 and accrued interest of approximately $100,000 for promissory notes of the Company on substantially similar terms to those of the 2022 Notes (the “Exchanged Notes”). As of July 6, 2022, $699,781 of principal and accrued interest of the Series 2 notes was exchanged for the Exchanged Notes.

 

On March 10, 2023, the Company entered into an amendment (the “Series 2 Note Amendment” and, together with the Series 1 Amendment, the “Series Note Amendments”) with each of the holders of the Company’s outstanding Series 2 Convertible Notes (as amended, the “Series 2 Notes” and, together with the Series 1 Notes, the “Series Convertible Notes”). Pursuant to the Series Note Amendments, the Company can elect to convert the principal and accrued interest under the Series Convertible Notes (the “Series Note Obligations”) at or after the effective time of the Uplisting Transaction, or the maturity date. In the event the Company exercises such option, the Series Note Obligations will be deemed to equal the product of 4.5 (which was previously 1.6 prior to the Series Note Amendments) and the outstanding Series Note Obligations. Notwithstanding the foregoing, if the registration statement filed in connection with the Uplist Transaction is not declared effective by 11:59 P.M. (EST) on or before the Uplisting Transaction deadline under the 2022 Notes and Second Notes, which was originally February 15, 2023, or such later extended date as provided for therein (the “Series Note Amendments Termination Date”), the Series Note Amendments will automatically terminate without any further action by the Company or the holders of the Series Convertible Notes. The Series Note Amendments Termination Date will be automatically extended upon any extension of the Uplisting Transaction deadline under the 2022 Notes and Second Notes. As previously discussed herein, the deadline to complete the Uplist Transaction was extended on multiple previous occasions. As of May 15, 2023 the Uplist Transaction deadline under the 2022 Notes and Second Notes is June 15, 2023. No consideration was paid by the Company in connection with any of the extensions of the Uplisting Transaction deadline under the 2022 Note and Second Notes.

 

During the three months ended March 31, 2023 and 2022, the Company recorded interest expense on the Series Convertible Notes of approximately $25,000 and $39,000, respectively. During the six months ended March 31, 2023 and 2022, the Company recorded interest expense on the Series Convertible Notes of approximately $50,000 and $80,000, respectively.

 

-17-

 

 

 

13. RISKS AND UNCERTAINTIES COVID-19 AND GEOPOLITICAL CONFLICTS

 

The Company sources its materials and services for its products and product candidates from facilities in areas impacted or which may be impacted by the outbreak of the COVID-19 or geopolitical conflicts. The Company’s ability to obtain future inventory may be impacted, therefore potentially affecting the Company’s future revenue stream. In addition, the Company has historically and principally funded its operations through debt borrowings, the issuance of convertible debt, and the issuance of units consisting of Common Stock and warrants which may also be impacted by economic conditions beyond the Company’s control as well as uncertainties resulting from geopolitical conflicts, including the recent war in Ukraine. The extent to which the COVID-19 and recent events in Ukraine will impact the global economy and the Company is uncertain and cannot be reasonably measured.

 

 

14. SHAREHOLDER ADVANCES

 

During the three months ended March 31, 2023, the Company raised $230,000 in the form of shareholder advances from two different investors to support operations in advance of the Company’s prospective Uplisting Transaction. During April 2023 and May 2023, the Company raised an additional $308,000 in shareholder advances from a single investor resulting in the Company raising a total of $538,000 in the form of shareholder advances, $488,000 of which was contributed by a single investor, who was subsequently issued an Unsecured convertible note (the “Third Note”) in connection with the Third Closing of the 2022 Convertible Note Offering (see Note 15). Finally, on May 18, 2023, the Company received an additional advance from a third party of $350,000, which is expected to be rolled into an anticipated near-term capital raise not related to the prior 2022 Convertible Note Offering. The remaining $50,000 raised by the Company in the form of shareholder advances is expected to be repaid from proceeds expected to be received in connection with the anticipated near-term capital raise not related to the prior 2022 convertible note offering.

 

 

15. SUBSEQUENT EVENTS

 

On April 15, 2023, Arch Therapeutics, Inc. (the “Company”) entered into an amendment (“Amendment No. 4 to the First Notes”) with the holders of the Company’s outstanding 2022 Notes, as amended on February 14, 2023, March 10, 2023 and March 15, 2023 issued in connection with a private placement financing the Company completed on July 6, 2022 (the “First Closing”). On April 15, 2023, the Company also entered into an amendment (“Amendment No. 4 to the Second Notes” and, together with Amendment No. 4 to the First Notes, “Amendment No. 4 to the 2022 Notes”) with the holders of the Company’s outstanding Second Notes, as amended on February 14, 2023, March 10, 2023 and March 15, 2023 issued in connection with a private placement financing the Company completed on January 18, 2023 (the “Second Closing”).

 

Under Amendment No. 4 to the 2022 Notes, the 2022 Notes and the Second Notes were amended to extend the date of the completion of an uplist to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American (such transaction, an “Uplist Transaction”) from April 15, 2023 to May 15, 2023.

 

As a result of the entry into Amendment No. 4 to the 2022 Notes, and pursuant to the terms of the Company’s outstanding Exchanged Notes, the Exchanged Notes were automatically amended to extend the date of completion of an Uplist Transaction from April 15, 2023 to May 15, 2023. Also, on April 15, 2023, in connection with Amendment No. 4 to the 2022 Notes, the Series Note Amendments Termination Date set forth under Amendment No. 1 to the Series 1 Unsecured Convertible Promissory Notes and Amendment No. 1 of the Series 2 Unsecured Convertible Promissory Notes was automatically extended from April 15, 2023 to May 15, 2023.

 

On April 15, 2023, the Company entered into an amendment (“Amendment No. 1 to the A&R Registration Rights Agreement”) to that certain Amended and Restated Registration Rights Agreement, dated as of January 18, 2023, by and among the Company and certain institutional and accredited individual investors (as amended, the “A&R Registration Rights Agreement”). Under Amendment No. 1 to the A&R Registration Rights Agreement, the A&R Registration Rights Agreement was amended to extend the filing deadline by which the Company is obligated to file with the Securities and Exchange Commission a registration statement under the Securities Act of 1933, as amended, registering certain securities issued in the Second Closing, from April 18, 2023 to June 17, 2023.

 

On May 15, 2023, the Company entered into Amendment No. 2 to the 2022 SPA related to the 2022 Convertible Note Offering (the “Amendment” and, together with the 2022 SPA, the “Amended 2022 SPA”), with certain Investors in connection with the Third Closing of the 2022 Convertible Note Offering for the issuance and sale by the Company to an Investor of an aggregate of (i) Unsecured Convertible Promissory Notes (each a “Third Note” and collectively, the “Third Notes”) in the aggregate principal amount of $702,720, which includes an aggregate $214,720 original issue discount in respect of the Third Notes; (ii) warrants (the “Third Warrants”) to purchase an aggregate of 141,396 shares (the “Warrant Shares”) of Common Stock; and (iii) 10,608 shares of Common Stock (the “Third Inducement Shares”). The aggregate gross proceeds for the sale of the Third Notes, Third Warrants and Third Inducement Shares was approximately $488,000, before deducting any placement agent’s fees and other estimated fees and offering expenses payable by the Company. The third closing of the sales of these securities under the Amended SPA occurred on May 15, 2023 (the “Third Closing Date”).

 

On May 15, 2023, the Company entered into an amendment (“Amendment No. 5 to the First Notes”) with the holders of the Company’s outstanding 2022 Notes, as amended on February 14, 2023, March 10, 2023, March 15, 2023 and April 15, 2023 issued in connection with a private placement financing the Company completed on July 6, 2022 (the “First Closing”) to extend the date of the completion of the Uplist Transaction from May 15, 2023 to June 15, 2023.

 

On May 15, 2023, the Company also entered into an amendment (“Amendment No. 5 to the Second Notes” and, together with Amendment No. 5 to the First Notes, “Amendment No. 5 to the 2022 Notes”) with the holders of the Company’s outstanding Second Notes, as amended on February 14, 2023, March 10, 2023, March 15, 2023 and April 15, 2023, issued in connection with a private placement financing the Company completed on January 18, 2023 (the “Second Closing”) to extend the date of the completion of the Uplist Transaction from May 15, 2023 to June 15, 2023.

 

On May 15, 2023, as a result of the entry into Amendment No. 5 to the 2022 Notes, and pursuant to the terms of the Company’s outstanding Exchanged Notes, the Exchanged Notes were automatically amended to extend the date of completion of an Uplist Transaction from May 15, 2023 to June 15, 2023. Also, on May 15, 2023, in connection with Amendment No. 5 to the 2022 Notes, the Series Note Amendments Termination Date set forth under Amendment No. 1 to the Series 1 Unsecured Convertible Promissory Notes and Amendment No. 1 of the Series 2 Unsecured Convertible Promissory Notes was automatically extended from May 15, 2023 to June 15, 2023.

 

On May 18, 2023, the Company received an additional advance from a third party of $350,000, which is expected to be rolled into an anticipated near-term capital raise not related to the prior 2022 Convertible Note Offering.

 

 

-18-

 

 

 

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

 

References in this Quarterly Report on Form 10-Q (this "Quarterly Report", or this "Report") to "Arch Biosurgery, Inc." Company, we, us, our, Arch or similar references mean Arch Therapeutics, Inc. and its consolidated subsidiary, Arch Biosurgery, Inc.  References to the "SEC" refer to the U.S. Securities and Exchange Commission.

 

Forward Looking Statements

 

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated condensed financial statements and the related notes included elsewhere in this Report. Our consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including, without limitation, statements regarding our expectations, beliefs, intentions or future strategies that are signified by the words expect, anticipate, intend, believe, or similar language. All forward-looking statements included in this Report are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Our business and financial performance are subject to substantial risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. In evaluating our business, you should carefully consider the information set forth under the heading Risk Factors included Part I, Item 1A of our Annual Report on Form 10-K for the year ended September 30, 2022 (the "Annual Report”), as well as in Item II, Part 1A of this Report. Readers are cautioned not to place undue reliance on these forward-looking statements.

 

AC5, AC5-G, AC5-V, AC5-P, Crystal Clear Surgery, NanoDrape and NanoBioBarrier and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and its subsidiary. For purposes herein, references to regulatory approval and marketing authorization may be used interchangeably.

 

Corporate Overview

 

Arch Therapeutics, Inc., (together with its subsidiary, the “Company” or “Arch”) was incorporated under the laws of the State of Nevada on September 16, 2009, under the name “Almah, Inc.”. Effective June 26, 2013, the Company completed a merger (the “Merger”) with Arch Biosurgery, Inc. (formerly known as Arch Therapeutics, Inc.), a Massachusetts corporation (“ABS”), and Arch Acquisition Corporation (“Merger Sub”), the Company’s wholly owned subsidiary formed for the purpose of the transaction, pursuant to which Merger Sub merged with and into ABS and ABS thereby became the wholly owned subsidiary of the Company. As a result of the acquisition of ABS, the Company abandoned its prior business plan and changed its operations to the business of a biotechnology company. Our principal offices are located in Framingham, Massachusetts.

 

ABS was incorporated under the laws of the Commonwealth of Massachusetts on March 6, 2006, as Clear Nano Solutions, Inc. On April 7, 2008, ABS changed its name from Clear Nano Solutions, Inc. to Arch Therapeutics, Inc. Effective upon the closing of the Merger, ABS changed its name from Arch Therapeutics, Inc. to Arch Biosurgery, Inc.

 

In the first quarter of 2021, the Company commenced commercial sales of our first product, AC5® Advanced Wound System, and has devoted substantially all of our operational effort to the research, development and regulatory programs necessary to turn our core technology into commercial products. To date, the Company has principally raised capital through debt borrowings, the issuance of convertible debt, and the issuance of units consisting of the Company's common stock, $0.001 par value per share (“Common Stock”), and warrants to purchase Common Stock (“warrants”).

 

The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential products. However, there can be no assurance that the Company will be successful in securing additional resources when needed, on terms acceptable to the Company, if at all. Therefore, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments related to the recoverability of assets that might be necessary despite this uncertainty.

 

Business Overview

 

We are a biotechnology company marketing and developing a number of products based on our innovative AC5® self-assembling technology platform. We believe these products can be important advances in the field of stasis and barrier applications, which includes stopping bleeding (“hemostasis”), controlling leaking (“sealant”), and managing wounds created during surgery, trauma or interventional care, or from disease. We have only recently commenced commercial sales of our first product, AC5® Advanced Wound System, and have devoted substantially all of our operational effort to the research, development and regulatory programs necessary to turn our core technology into commercial products. Our goal is to make care faster and safer for patients with products for use on external wounds, which we refer to as Dermal Sciences applications, and products for use inside the body, which we refer to as BioSurgery applications.

 

-19-

 

 

Core Technology

 

Our flagship products and product candidates are derived from our AC5® self-assembling peptide (“SAP”) technology platform and are sometimes referred to as AC5 or the “AC5 Devices.” These include AC5® Advanced Wound System and AC5® Topical Hemostat, which have received marketing authorization as medical devices in the United States and Europe, respectively, and which are intended for skin applications, such as the management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures, and include, for example, AC5-G™ for gastrointestinal endoscopic procedures, and AC5-V® and AC5® Surgical Hemostat for hemostasis inside the body, all of which are currently investigational devices limited by law to investigational use.

 

Products based on AC5 platform contain a biocompatible peptide that is synthesized from proteogenic, naturally occurring L-amino acids. Unlike products that contain traditional peptide sequences, when applied to a wound, AC5-based products intercalate into the interstices of the connective tissue and self-assemble into a protective physical-mechanical nanoscale structure that can provide a barrier to leaking substances, such as blood, while also acting as a biodegradable scaffold that enables healing. Self-assembly is a central component of the mechanism of action of our technology. Individual AC5 peptide units readily build themselves, or self-assemble, into an ordered network of nanofibrils when in aqueous solution by the following process:

 

 

Peptide strands line up with neighboring peptide strands, interacting via hydrogen bonds (non-covalent bonds) to form a ribbon-like structure called a beta sheet.

 

 

This process continues such that hundreds of strands organize with charged and polar side chains oriented on one face and non-polar side chains oriented on the opposite face of the beta sheets.

 

 

Interactions of the resulting structure with water molecules and ions results in formation nanofibrils, which extend in length and can join together to form larger nanofibers.

 

 

This network of AC5 peptide nanofibers forms the semi-solid physical-mechanical barrier that interacts with the extracellular matrix, is responsible for sealant, hemostatic and other properties, regardless of the presence of antithrombotic agents, and which subsequently becomes the scaffold that supports the repair and regeneration of damaged tissue.

 

Based on the intended application, we believe that the underlying AC5 SAP technology can impart important features and benefits to our products that may include, for instance, stopping bleeding (hemostasis), mitigating contamination, modulating inflammation, donating moisture, and enabling an appropriate wound microenvironment conducive to healing. Furthermore, we believe that AC5® SAP technology permits cell and tissue growth and is self-healing, in that it can dynamically self-repair around migrating cells. For instance, AC5® Advanced Wound System, which is indicated for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds, is shipped and stored at room temperature, is applied directly as a liquid, can conform to irregular wound geometry, self-assembles into a wound care matrix that can provide clinicians with multi-modal support, and does not possess sticky or glue-like handling characteristics. We believe these properties enhance its utility in several settings and contribute to its user-friendly profile.

 

We believe that our technology lends itself to a range of potential applications in which there is a wound inside or on the body, and in which there is need for a hemostatic agent or sealant. For instance, the results of certain preclinical and clinical investigations that either we have conducted, or others have conducted on our behalf, have shown quick and effective hemostasis with the use of AC5 SAP technology, and that time to hemostasis is comparable among test subjects regardless of whether such test subject had or had not been treated with therapeutic doses of anticoagulant or antiplatelet medications, commonly called “blood thinners.” Furthermore, the transparency and physical properties of certain AC5 Devices may enable a surgeon to operate through it in order to maintain a clearer field of vision and prophylactically stop or lessen bleeding as surgery starts, a concept that we call Crystal Clear Surgery™. An example of a product that contains related features and benefits is AC5 Topical Hemostat, which is indicated for use as a dressing and to control mild to moderate bleeding, each during the management of injured skin and the micro-environment of an acute surgical wound.

 

Operations

 

Much of our operational efforts to date, which we often perform in collaboration with partners, have included selecting compositions and formulations for our initial products; conducting preclinical studies, including safety and other tests; conducting a human trial for safety and performance of AC5; developing and conducting a human safety study to assess for irritation and sensitization potential; securing marketing authorization for our first product in the United States and in Europe; developing, optimizing, and validating manufacturing methods and formulations, which are particularly important components of self-assembling peptide development; developing methods for manufacturing scale-up, reproducibility, and validation; engaging with regulatory authorities to seek early regulatory guidance as well as marketing authorization for our products; sourcing and evaluating commercial partnering opportunities in the United States and abroad; and developing and protecting the intellectual property rights underlying our technology platform.

 

-20-

 

 

Our long-term business plan includes the following goals:

 

 

conducting biocompatibility, pre-clinical, and clinical studies on our products and product candidates;

 

 

obtaining additional marketing authorization for products in the United States, Europe, and other jurisdictions as we may determine;

 

 

continuing to develop third party relationships to manufacture, distribute, market and otherwise commercialize our products;

 

 

continuing to develop academic, scientific and institutional relationships to collaborate on product research and development;

 

 

expanding and maintaining protection of our intellectual property portfolio; and

 

 

developing additional product candidates in Dermal Sciences, BioSurgery, and other areas.

 

In furtherance of our long-term business goals, we expect to continue to focus on the following activities during the next twelve months:

 

 

seek additional funding as required to support the previously described milestones necessary to support operations;

 

 

work with our manufacturing partners to scale up production of product compliant with current good manufacturing practices (“cGMP”), which activities will be ongoing and tied to our development and commercialization needs;

 

 

further clinical development of our product platform;

 

 

assess our technology platform in order to identify and select product candidates for potential advancement into development;

 

 

seek regulatory input to guide activities related to expanded and new product marketing authorizations;

 

 

continue to expand and enhance our financial and operational reporting and controls;

 

 

pursue commercial partnerships; and

 

 

expand and enhance our intellectual property portfolio by filing new patent applications, obtaining allowances on currently filed patent applications, and/or adding to our trade secrets in self-assembly, manufacturing, analytical methods and formulation, which activities will be ongoing as we seek to expand our product candidate portfolio.

 

We have no commitments for any future capital. We will require significant additional financing to fund our planned operations, including further research and development relating to AC5®, seeking regulatory approval of any product we may choose to develop, commercializing any product for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or business, and maintaining our intellectual property rights, pursuing new technologies and for financing the investor relations and incremental administrative costs associated with being a public corporation.

 

The estimated capital requirements potentially could increase significantly if a number of risks relating to conducting these activities were to occur, including without limitation those set forth under the heading “RISK FACTORS” in our Annual Report. We anticipate that our operating and other expenses will continue to increase as we continue to implement our business plan and pursue and achieve these goals. We could spend our financial resources much faster than we expect, in which case we would need to raise additional capital as our current funds may not be sufficient to operate our business for the entire duration of that period.

 

-21-

 

 

Manufacturing

 

We work with contract manufacturing and related organizations, including those operating under cGMP, as is required by applicable regulatory agencies for production of product that can be used for preclinical and human testing as well as for commercial use. We also have engaged and continue to engage other third parties in the United States and abroad to advise on and perform certain manufacturing and related activities, typically with assistance from our team. These third parties include academic institutions, consultants, advisors, scientists, and/or other collaborators. The activities include development of our primary product candidates, as well as generation of appropriate analytical methods, scale-up, and other procedures for use by manufacturers and/or other members of our supply chain to produce or process our products at current and/or larger scale quantities for preclinical and clinical testing and ultimately, as required marketing authorizations are obtained, commercialization.

 

Our products are regulated as medical devices, and as such, many of our activities have focused on optimizing traditional parameters to target specifications, biocompatibility, physical appearance, stability, and handling characteristics, among other metrics, to achieve the desired product. We and our partners intend to continue to monitor manufacturing processes and formulation methods closely, as success or failure in establishing and maintaining appropriate specifications may directly impact our ability to conduct additional preclinical and clinical trials and/or deliver commercial product.

 

Merger with ABS and Related Activities

 

On June 26, 2013, the Company completed the Merger with ABS, pursuant to which ABS became a wholly owned subsidiary of the Company. In contemplation of the Merger, effective May 24, 2013, the Company increased its authorized Common Stock, from 375,000 shares to 1,500,000 shares and effected a forward stock split, by way of a stock dividend, of its issued and outstanding shares of Common Stock at a ratio of 11 shares to each 1 issued and outstanding share. Also, in contemplation of the Merger, effective June 5, 2013, the Company changed its name from Almah, Inc. to Arch Therapeutics, Inc. and changed the ticker symbol under which its Common Stock trades on the OTC Bulletin Board from “AACH” to “ARTH”.

 

Recent Developments

 

On January 13, 2023, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, with the Secretary of State of the State of Nevada (the “Certificate of Change”), which effected, at 5:00 p.m. Eastern Time on January 17, 2023, a one-for-two-hundred (1:200) reverse stock split (the “Reverse Stock Split”) of both the Company’s issued and outstanding shares of Common Stock, and authorized shares of Common Stock.

 

As a result of the Reverse Stock Split, every two hundred (200) shares of Common Stock issued and outstanding was combined into one (1) share of Common Stock, with a proportionate 1:200 reduction in the Company’s authorized Common Stock. The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the Reverse Stock Split would have resulted in some stockholders owning a fractional share. No fractional shares were issued in connection with the Reverse Stock Split.  Any fractional shares of Common Stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share and no stockholders received cash in lieu of fractional shares.

 

-22-

 

 

The Reverse Stock Split did not change the par value of the Common Stock. All outstanding securities entitling their holders to purchase shares of Common Stock or acquire shares of Common Stock, including stock options, restricted stock units, and warrants, were adjusted as a result of the Reverse Stock Split, as required by the terms of those securities.

 

On January 13, 2023, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Nevada to increase the number of authorized shares of Common stock from 4,000,000 shares to 12,000,000 shares. The increase in the number of authorized shares was approved by the Company’s stockholders on September 29, 2022.

 

As previously disclosed in footnote 11 in this Form 10-Q, the Company entered into a Securities Purchase Agreement, dated July 6, 2022 (“SPA”), with certain institutional and accredited individual investors (collectively, the “Investors”) for the issuance and sale by the Company to the Investors of convertible promissory notes, warrants to purchase shares of common stock, par value $0.001 per share (the “Common Stock”), and shares of Common Stock (the “2022 Convertible Note Offering”). The First Closing of the 2022 Convertible Note Offering occurred on July 6, 2022.

 

On January 18, 2023, the Company entered into Amendment No. 1 to the 2022 SPA (the “Amendment” and, together with the SPA, the “Amended 2022 SPA”), with certain Investors in connection with the second closing of the 2022 Convertible Note Offering for the issuance and sale by the Company to such Investors of an aggregate of (i) Unsecured Convertible Promissory Notes (each a “Second Note” and collectively, the “Second Notes”) in the aggregate principal amount of $636,000, which includes an aggregate $106,000 original issue discount in respect of the Second Notes; (ii) warrants (the “Second Warrants”) to purchase an aggregate of 127,968 shares (the “Second Warrant Shares”) of Common Stock; and (iii) 9,598 shares of Common Stock (the “Second Inducement Shares”). The aggregate gross proceeds for the sale of the Second Notes, Second Warrants and Second Inducement Shares was approximately $530,000, before deducting any placement agent’s fees and other estimated fees and offering expenses payable by the Company. The second closing of the sales of these securities under the Amended SPA occurred on January 18, 2023 (the “Second Closing Date”).

 

On February 14, 2023, the Company entered into an amendment to its outstanding 2022 Notes issued on July 6, 2022 with the holders of such notes. Also on February 14, 2023, the Company entered into an amendment to its outstanding Second Notes issued on January 18, 2023 with the holders of such notes. These actions amended the 2022 Notes and Second Notes to extend the Uplist Transaction deadline related to the Company’s efforts to uplist to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American from February 15, 2023 to March 15, 2023.

 

As a result of the amendment to the 2022 Notes and Second Notes, and pursuant to the terms of the Company’s outstanding Exchanged Notes, the Exchanged Notes were automatically amended to extend the date of completion of an Uplist Transaction from February 15, 2023 to March 15, 2023.

 

On March 10, 2023, the Company entered into exchange agreements (the “Exchange Agreements”) with each holder (the “Warrantholders”) of the Company’s outstanding Series G Warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at an exercise price of $140.00 per share and the Company’s outstanding Series H Warrants to purchase shares of Common Stock at an exercise price of $80.00 per share. Pursuant to the Exchange Agreements, the Warrantholders exchanged 34,013 Series G Warrants for 3,402 shares of Common Stock and 43,077 Series H Warrants for 8,617 shares of Common Stock.

 

On March 10, 2023, the Company entered into an amendment (“Amendment No. 2 to the First Notes”) with the Requisite Holders of the Company’s outstanding 2022 Notes, as amended on February 14, 2023 issued in connection with a private placement financing the Company completed on July 6, 2022 (the “First Closing”). On March 10, 2023, the Company also entered into an amendment (“Amendment No. 2 to the Second Notes” and, together with Amendment No. 2 to the First Notes, “Amendment No. 2 to the 2022 Notes”) with the Requisite Holders of Company’s Second Notes, as amended on February 14, 2023, issued in connection with a private placement financing the Company completed on January 18, 2023 (the “Second Closing” and, together with the First Closing, the “2022 Convertible Note Offering”).

 

On March 15, 2023, the Company entered into amendments to the 2022 Notes (“Amendment No. 3 to the First Notes”) and Second Notes (“Amendment No. 3 to the Second Notes” and collectively, “Amendment No. 3 to the 2022 Notes” and, together with Amendment No. 2 to the 2022 Notes, the “Amendments to the 2022 Notes”) with the Requisite Holders of the 2022 Notes and Second Notes. Under Amendment No. 3 to the 2022 Notes, the 2022 Notes were amended to extend the Amendment No. 2 Termination Date from March 15, 2023 to April 15, 2023, which had the effect of extending to Uplist Transaction deadline from March 15, 2023 to April 15, 2023. In connection with Amendment No. 3 to the 2022 Notes, the Series Note Amendments Termination Date set forth under Amendment No. 1 to the Series 1 Unsecured Convertible Promissory Notes and Amendment No. 1 of the Series 2 Unsecured Convertible Promissory Notes was automatically extended from March 15, 2023 to April 15, 2023.

 

As a result of the entry into the Amendments to the 2022 Notes, and pursuant to the terms of the Company’s outstanding Exchanged Notes, the Exchanged Notes were automatically amended to (i) extend the Amendment No. 2 Termination Date from March 15, 2023 to April 15, 2023; (ii) modify the terms of the Uplist Transaction repayment provision; and (iii) provide for the issuance of the 2023 Notes, subject to completion of the Uplist Transaction.

 

Also, on March 15, 2023, in connection with Amendment No. 3 to the 2022 Notes, the Series Note Amendments Termination Date set forth under Amendment No. 1 to the Series 1 Unsecured Convertible Promissory Notes and Amendment No. 1 of the Series 2 Unsecured Convertible Promissory Notes was automatically extended from March 15, 2023 to April 15, 2023.

 

On April 15, 2023, the Company entered into an amendment (“Amendment No. 4 to the First Notes”) with the holders of the Company’s outstanding 2022 Notes, as amended on February 14, 2023, March 10, 2023 and March 15, 2023, issued in connection with a private placement financing the Company completed on July 6, 2022 (the “First Closing”). On April 15, 2023, the Company also entered into an amendment (“Amendment No. 4 to the Second Notes” and, together with Amendment No. 4 to the First Notes, “Amendment No. 4 to the 2022 Notes”) with the holders of the Company’s outstanding Second Notes, as amended on February 14, 2023, March 10, 2023 and March 15, 2023 issued in connection with a private placement financing the Company completed on January 18, 2023 (the “Second Closing”).

 

-23-

 

Under Amendment No. 4 to the 2022 Notes, the 2022 Notes and Second Notes were amended to extend the date of the completion of an uplist to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American (such transaction, an “Uplist Transaction”) from April 15, 2023 to May 15, 2023.

 

As a result of the entry into Amendment No. 4 to the 2022 Notes, and pursuant to the terms of the Company’s outstanding Exchanged Notes, the Exchanged Notes were automatically amended to extend the date of completion of an Uplist Transaction from April 15, 2023 to May 15, 2023. Also, on April 15, 2023, in connection with Amendment No. 4 to the 2022 Notes, the Series Note Amendments Termination Date set forth under Amendment No. 1 to the Series 1 Unsecured Convertible Promissory Notes and Amendment No. 1 of the Series 2 Unsecured Convertible Promissory Notes was automatically extended from April 15, 2023 to May 15, 2023.

 

On April 15, 2023, the Company entered into an amendment (“Amendment No. 1 to the A&R Registration Rights Agreement”) to that certain Amended and Restated Registration Rights Agreement, dated as of January 18, 2023, by and among the Company and certain institutional and accredited individual investors (as amended, the “A&R Registration Rights Agreement”). Under Amendment No. 1 to the A&R Registration Rights Agreement, the A&R Registration Rights Agreement was amended to extend the filing deadline by which the Company is obligated to file with the Securities and Exchange Commission a registration statement under the Securities Act of 1933, as amended, registering certain securities issued in the Second Closing, from April 18, 2023 to June 17, 2023.

 

On May 15, 2023, the Company entered into Amendment No. 2 to the 2022 SPA related to the 2022 Convertible Note Offering (the “Amendment” and, together with the 2022 SPA, the “Amended 2022 SPA”), with certain Investors in connection with the third closing of the 2022 Convertible Note Offering for the issuance and sale by the Company to an Investor of an aggregate of (i) Unsecured Convertible Promissory Notes (each a “Third Note” and collectively, the “Third Notes”) in the aggregate principal amount of $702,720, which includes an aggregate $214,720 original issue discount in respect of the Third Notes; (ii) warrants (the “Third Warrants”) to purchase an aggregate of 141,396 shares (the “Third Warrant Shares”) of Common Stock; and (iii) 10,608 shares of Common Stock (the “Third Inducement Shares”). The aggregate gross proceeds for the sale of the Third Notes, Third Warrants and Third Inducement Shares was approximately $488,000, before deducting the placement agent’s fees and other estimated fees and offering expenses payable by the Company. The third closing of the sales of these securities under the Amended SPA occurred on May 15, 2023 (the “Third Closing Date”).

 

On May 15, 2023, the Company entered into an amendment (“Amendment No. 5 to the First Notes”) with the holders of the Company’s outstanding 2022 Notes, as amended on February 14, 2023, March 10, 2023, March 15, 2023 and April 15, 2023, issued in connection with a private placement financing the Company completed on July 6, 2022 (the “First Closing”) to extend the date of the completion of the Uplist Transaction from May 15, 2023 to June 15, 2023. In connection with Amendment No. 5 to the 2022 Notes, the Series Note Amendments Termination Date set forth under Amendment No. 1 to the Series 1 Unsecured Convertible Promissory Notes and Amendment No. 1 of the Series 2 Unsecured Convertible Promissory Notes was automatically extended from May 15, 2023 to June 15, 2023.

 

On May 15, 2023, the Company also entered into an amendment (“Amendment No. 5 to the Second Notes” and, together with Amendment No. 5 to the First Notes, “Amendment No. 5 to the 2022 Notes”) with the holders of the Company’s outstanding Second Notes, as amended on February 14, 2023, March 10, 2023, March 15, 2023 and April 15, 2023 issued in connection with a private placement financing the Company completed on January 18, 2023 (the “Second Closing”) to extend the date of the completion of the Uplist Transaction from May 15, 2023 to June 15, 2023.

 

As a result of the entry into Amendment No. 5 to the 2022 Notes, and pursuant to the terms of the Company’s outstanding Exchanged Notes, the Exchanged Notes were automatically amended to extend the date of completion of an Uplist Transaction from May 15, 2023 to June 15, 2023. Also, on May 15, 2023, in connection with Amendment No. 5 to the 2022 Notes, the Series Note Amendments Termination Date set forth under Amendment No. 1 to the Series 1 Unsecured Convertible Promissory Notes and Amendment No. 1 of the Series 2 Unsecured Convertible Promissory Notes was automatically extended from May 15, 2023 to June 15, 2023.

 

On May 18, 2023, the Company received an additional advance from a third party of $350,000, which is expected to be rolled into an anticipated near-term capital raise not related to the prior 2022 Convertible Note Offering.

 

Results of Operations

 

The following discussion of our results of operations should be read together with the unaudited interim consolidated financial statements included in this Report. The period-to-period comparisons of our interim results of operations that follow are not necessarily indicative of future results.

 

Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022

 

   

March 31,

   

March 31,

   

Increase

 
   

2023

   

2022

   

(Decrease)

 
   

($)

   

($)

   

($)

 

Revenue

    16,654       3,130       13,524  

Operating Expense:

                       

Cost of revenues

    18,718       17,430       1,288  

Selling, general and administrative

    1,252,786       1,208,910       43,876  

Research and development

    170,634       527,656       (357,022

)

Loss from Operations

    (1,425,484

)

    (1,750,866

)

    (325,382

)

Other Income

    523,007       960,548       (437,541

)

Net loss

    (902,477

)

    (790,318

)

    112,159  

 

Revenue

 

Revenue for the three months ended March 31, 2023 was $16,654, an increase of $13,524 compared to revenue of $3,130 for the three months ended March 31, 2022. Revenue for the three months ended March 31, 2023 and 2022 was the result of transactions into VA Hospitals through our distribution partner, Lovell Government Services (“LGS”).

 

Cost of Revenue

 

Cost of revenue during the three months ended March 31, 2023 was $18,718, an increase of $1,288 compared to cost of revenue of $17,430 for the three months ended March 31, 2022. Cost of revenue includes product costs, third party warehousing, overhead allocation, royalty and shipping costs.

 

-24-

 

 

Selling, General and Administrative Expense

 

Selling, general and administrative expense during the three months ended March 31, 2023 was $1,252,786, an increase of $43,876 compared to $1,208,910 for the three months ended March 31, 2022. The increase in selling, general and administrative expense for the three months ended March 31, 2023 is primarily attributable to an increase in consulting cost.

 

Research and Development Expense

 

Research and development expense during the three months ended March 31, 2023 was $170,634 a decrease of $357,022 compared to $527,656 for the three months ended March 31, 2022. The decrease in research and development expense is primarily attributable to a decrease in compensation costs attributed to a reduction in headcount. 

 

Other (Expense) Income

 

Other income during the three months ended March 31, 2023 was $523,007, a decrease of $437,541 compared to other income of $960,548 for the three months ended March 31, 2022. The decrease in other income is primarily attributed to an increase in interest expense related to the 2022 Notes and Second Notes offset by a gain for the extinguishment of the Series G warrants and Series H warrants derivative liabilities during the three months ended March 31, 2023 and the impact of the expiration of the Series F warrants during the three months ended March 31, 2022.

 

 

Six Months Ended March 31, 2023 Compared to Six Months Ended March 31, 2022

 

   

March 31,

   

March 31,

   

Increase

 
   

2023

   

2022

   

(Decrease)

 
   

($)

   

($)

   

($)

 

Revenue

    22,914       7,826       15,088  

Operating Expense:

                       

Cost of revenues

    36,353       34,223       2,130  

Selling, general and administrative

    2,355,701       2,472,013       (116,312

)

Research and development

    332,087       762,274       (430,187

)

Loss from Operations

    (2,701,227

)

    (3,260,684

)

    559,457  

Other (Expense) Income

    (1,306

)

    920,219       921,525  

Net loss

    (2,702,533

)

    (2,340,465

)

    362,068  

 

Revenue

 

Revenue for the six months ended March 31, 2023 was $22,914, an increase of $15,088 compared to revenue of $7,826 for the six months ended March 31, 2022. Revenue for the six months ended March 31, 2023 and 2022 was primarily the result of transactions into VA Hospitals through our distribution partner, LGS.

 

Cost of Revenue

 

Cost of revenue during the six months ended March 31, 2023 was $36,353, an increase of $2,130 compared to cost of revenue of $34,223 for the six months ended March 31, 2022. Cost of revenue includes product costs, third party warehousing, overhead allocation, royalty and shipping costs.

 

-25-

 

 

Selling, General and Administrative Expense

 

Selling, general and administrative expense during the six months ended March 31, 2023 was $2,355,701, a decrease of $116,312 compared to $2,472,013 for the six months ended March 31, 2022. The decrease in selling, general and administrative expense for the six months ended March 31, 2023 is primarily attributable to a decrease in compensation costs attributed to a reduction in headcount partially offset by an increase in consulting costs.

 

Research and Development Expense

 

Research and development expense during the six months ended March 31, 2023 was $332,087 a decrease of $430,187 compared to $762,274 for the six months ended March 31, 2022. The decrease in research and development expense is primarily attributable to a decrease in compensation costs attributed to a reduction in headcount. 

 

Other (Expense) Income

 

Other expense during the six months ended March 31, 2023 was $1,306 an increase of $921,525 compared to other income of $920,219 for the six months ended March 31, 2022. The increase in other (expense) income is primarily attributed to an increase in interest expense related to the 2022 Notes and Second Notes offset by a gain for the extinguishment of the Series G warrants and Series H warrants derivative liabilities during the three months ended March 31, 2023 and the impact of the expiration of the Series F warrants during the three months ended March 31, 2022.

 

Liquidity and Capital Resources

 

In the first quarter of 2021, the Company commenced commercial sales of our first product, AC5® Advanced Wound System. We devote a significant amount of our efforts on fundraising as well as planning and conducting product research and development and activities in connection with obtaining regulatory marketing authorization. We have principally raised capital through borrowings and the issuance of convertible debt and units consisting of Common Stock and warrants to fund our operations.

 

Working Capital

 

At March 31, 2023, we had total current assets of $1,588,228 (including cash of $29,495) and working capital deficit of $6,390,589. Our working capital as of March 31, 2023 and September 30, 2022 are summarized as follows:

 

 

   

March 31,

   

September 30,

 
   

2023

   

2022

 

Total Current Assets

  $ 1,588,228     $ 2,598,195  

Total Current Liabilities

    7,978,817       3,320,494  

Working Capital deficit

  $ (6,390,589

)

  $ (722,299

)

 

Total current assets as of March 31, 2023 were $1,588,228, a decrease of $1,009,967 compared to $2,598,195 as of September 30, 2022. The decrease in current assets is primarily attributable to selling, general and administrative expense and research and development expense incurred in connection with activities to develop our primary product candidate. Our total current assets as of March 31, 2023 and September 30, 2022 were comprised primarily of cash, inventory and prepaid expenses and other current assets.

 

Total current liabilities as of March 31, 2023 were $7,978,817, an increase of $4,658,323 compared to $3,320,494 as of September 30, 2022. The increase is primarily due to an increase in accounts payable, the current portion of the Series 2 Convertible Notes, the current portion of the 2022 Notes, current portion of the Unsecured convertible notes, which includes both the Second Notes and the Exchanged Notes, and the accrued interest associated with these notes partially offset by a decrease to the amount owed in connection with the financing of certain insurance premiums and the decrease in the fair value of the derivative liability resulting from the exchange of the Series G warrants into common stock.

 

Cash Flow for the Six months Ended March 31, 2023 Compared to the Six Months Ended March 31, 2022

 

   

March 31,

   

March 31,

 
   

2023

   

2022

 

Cash Used in Operating Activities

  $ (1,249,931

)

  $ (2,212,234

)

Cash Provided by Financing Activities

    532,486       -  

Net decrease in Cash

  $ (717,445

)

  $ (2,212,234

)

 

Cash Used in Operating Activities

 

Cash used in operating activities decreased by $962,303 to $1,249,931 during the six months ended March 31, 2023, compared to $2,212,234 during the six months ended March 31, 2022. The decrease in cash used in operating activities is primarily attributable the Company managing expenses and an increase in accounts payable and accrued interest.

 

-26-

 

 

Cash Used in Financing Activities

 

Cash provided by financing activities increased by $532,486 during the six months ended March 31, 2023, compared to no cash used in financing activities during the six months ended March 31, 2022. For the six months ended March 31, 2023, the cash provided by financing activities was attributable to the Second Closing of 2022 Convertible Note Offering and shareholder advances, which was partially offset by payments made in connection with the financing of certain insurance premiums.

 

 

Cash Requirements

 

We anticipate that our operating expenses, interest expense and other expenses will increase significantly as we continue to implement our business plan and pursue our operational goals. Depending upon additional input from EU and US regulatory authorities, however, we do not expect to generate sufficient revenues from operations before we will need to raise additional capital. Further, our estimates regarding our use of cash could change if we encounter unanticipated difficulties or other issues arise, including without limitation those set forth under the heading “RISK FACTORS” described in our Annual Report, in which case our current funds may not be sufficient to operate our business for the period we expect.

 

In the first quarter of 2021, the Company commenced commercial sales of our first product, AC5® Advanced Wound System. That revenue will not be sufficient to fund our business operations and we will need to obtain additional funding from external sources for the foreseeable future. We do not have any commitments for future capital. Significant additional financing will be required to fund our planned operations in the near term and in future periods, including research and development activities relating to our potential new product candidates, seeking regulatory approval of any other product candidates we may choose to develop, commercializing any product candidates for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We may not be able to obtain additional financing on commercially reasonable or acceptable terms when needed, or at all. We are bound by certain contractual terms and obligations that may limit or otherwise impact our ability to raise additional funding in the near-term including, but not limited to, provisions in the 2018 SPA (see Note 7) and the 2022 SPA (see Note 12) restricting our ability to effect or enter into an agreement to effect any issuance by the Company or any of its subsidiaries of Common Stock or securities convertible, exercisable or exchangeable for Common Stock (or a combination of units thereof) involving a Variable Rate Transaction. These restrictions and provisions could make it more challenging for us to raise capital through the incurrence of debt or through equity issuances. If we cannot raise the money that we need in order to continue to develop our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations. If any of these were to occur, there is a substantial risk that our business would fail, and our stockholders could lose all of their investments.

 

As previously noted, since inception we have funded our operations primarily through equity and debt financings and we expect to continue to seek to do so in the future. If we obtain additional financing by issuing equity securities, our existing stockholders’ ownership will be diluted. Additionally, the terms of securities we may issue in future capital-raising transactions may be more favorable for our new investors, and in particular may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have additional dilutive effects. If we obtain additional financing by incurring debt, we may become subject to significant limitations and restrictions on our operations pursuant to the terms of any loan or credit agreement governing the debt. Further, obtaining any loan, assuming a loan would be available when needed on acceptable terms, would increase our liabilities and future cash commitments. We may also seek funding from collaboration or licensing arrangements in the future, which may require that we relinquish potentially valuable rights to our product candidates or proprietary technologies or grant licenses on terms that are not favorable to us. Moreover, regardless of the manner in which we seek to raise capital, we may incur substantial costs in those pursuits, including investment banking fees, legal fees, accounting fees, printing and distribution expenses and other related costs.

 

Going Concern

 

We have commenced commercial sales of our first product, AC5® Advanced Wound System. From inception, we have had recurring losses from operations. The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations. As of March 31, 2023, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements included in this Annual Report do not include any adjustments that might be necessary should operations discontinue.

 

-27-

 

 

Critical Accounting Policies and Significant Judgments and Estimates

 

Pursuant to certain disclosure guidance issued by the SEC, the SEC defines “critical accounting policies” as those that require the application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Our critical accounting policies that we anticipate will require the application of our most difficult, subjective or complex judgments are as follows:

 

Inventories

 

Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, work-in-progress and finished goods and other products are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value.

 

Complex Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option-pricing model or other acceptable valuation models, including Monte-Carlo simulations. Derivative instruments are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is re-assessed at the end of each reporting period.

 

The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and warrants, including options or warrants to non-employees in exchange for consulting or other services performed.

 

The Company accounts for its common stock warrants in accordance with Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). Based upon the provisions of ASC 815, the Company accounts for common stock warrants as liabilities if the warrant requires net cash settlement or gives the holder the option of net cash settlement, or it fails the equity classification criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified as equity. Common stock warrants classified as liabilities are initially recorded at fair value on the grant date and remeasured at fair value each balance sheet date with the offset adjustments recorded in change in fair value of warrant liability within the consolidated statements of operations. Common stock warrants classified as equity are initially measured at fair value on the grant date and are not subsequently remeasured.

 

-28-

 

 

Off-Balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed by, or under the supervision of, the Principal Executive Officer and Principal Financial Officer and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control — Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations (“COSO”). We believe, that as of September 30, 2022.there existed a material weakness in our internal control over financial reporting. The deficiencies in the design of internal control over financial reporting related to a lack of sufficient resources with an understanding of the technical guidance under generally accepted accounting principles related to accounting for complex financial instruments within the 2022 Notes and certain accounting practices relating to the recording of the insurance premium advanced by a third party. Accordingly, the Audit Committee in consultation with management has determined that these matters may be best addressed by: (i) reviewing accounting literature and other technical materials to ensure that the appropriate personnel have a full awareness and understanding of the applicable accounting pronouncements and how they are to be implemented; (ii) additional education on new and existing accounting pronouncements and their application and (iii) requiring senior accounting staff and outside consultants with technical accounting experience to review complex transactions to evaluate and approve the accounting treatment of such transactions. Accordingly, the Board has recommended to management and management has agreed that the Company’s accounting staff, including its Chief Financial Officer, undertake additional training on an accelerated basis and that such training, in view of the complexity of certain generally accepted accounting principles and other matters be ongoing and engage third party specialists on an as-needed basis to help supplement the Company’s internal resources. During the quarter ended March 31, 2023 the Company engaged in active discussions with outside consultants with technical accounting expertise to review complex transactions and to evaluate the accounting treatment of such transactions. The parties remain in discussion to undertake a formal engagement which it expects to execute prior to the completion of the quarter ending June 30, 2023.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal controls over financial reporting that occurred during the quarter ended March 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. From time to time, we make changes to our internal control over financial reporting that are intended to enhance its effectiveness, and which do not have a material effect on our overall internal control over financial reporting.

 

-29-

 

 

PART II OTHER INFORMATION

 

Item 1. Legal Proceedings

 

In the ordinary course of business, we may become a party to legal proceedings involving various matters. We are unaware of any such legal proceedings presently pending to which we or our subsidiary is a party or of which any of our property is the subject that management deems to be, individually or in the aggregate, material to our financial condition or results of operations.

 

Item 1A. Risk Factors

 

In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” of our Annual Report, which could materially affect our business, financial condition or future results. The risks described in our Annual Report may not be the only risks facing the Company. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely affect the Company’s business, financial condition and/or operating results.

 

There were no material changes to the risk factors previously disclosed in our Annual Report.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Not applicable 

 

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 

 

On July 8, 2022, we entered into a Securities Purchase Agreement, dated July 6, 2022 (“2022 SPA”), with certain institutional and accredited individual investors (collectively, the “Investors”) for the issuance and sale by us to the Investors of convertible promissory notes, warrants to purchase shares of common stock, and shares of common stock (the “2022 Convertible Note Offering”). The first closing of the 2022 Convertible Note Offering occurred on July 6, 2022. The Second Closing of the 2022 Convertible Note Offering occurred on January 18, 2023.

 

On May 15, 2023, we entered into Amendment No. 2 to the 2022 SPA (the “Amendment” and, together with the 2022 SPA, the “Amended 2022 SPA”), with an Investor in connection with the third closing of the 2022 Convertible Note Offering for the issuance and sale by us to such Investors of an aggregate of (i) Unsecured Convertible Promissory Notes (each a “Third Note” and collectively, the “Third Notes”) in the aggregate principal amount of $702,720, which includes an aggregate $214,720 original issue discount in respect of the Third Notes; (ii) warrants (the “Third Warrants”) to purchase an aggregate of 141,396 shares (the “Third Warrant Shares”) of common stock; and (iii) 10,608 shares of common stock (the “Third Inducement Shares”). The aggregate gross proceeds for the sale of the Third Notes, Third Warrants and Third Inducement Shares was approximately $488,000 before deducting the estimated fees and offering expenses payable by us. The third closing of the sales of these securities under the Amended SPA occurred on May 15, 2023 (the “Third Closing Date”).

 

Use of Proceeds

 

The net proceeds to us from the Third Closing of the 2022 Convertible Note Offering, after deducting our estimated fees and offering expenses and excluding the proceeds, if any, from the conversion of the Third Notes and the exercise of the Third Warrants, was approximately $488,000. We intend to use the net proceeds from the Third Closing of the 2022 Convertible Note Offering primarily for working capital and general corporate purposes, and we have not allocated specific amounts for any specific purposes.

 

Third Notes

 

The Third Notes become due and payable on January 6, 2024 (the “Maturity Date”) and may not be prepaid, in whole or in part, at any time except with the written consent of the lead investor, with such prepayment amounts subject to adjustment as a result of certain time-based prepayment premiums set forth in the Third Notes; provided, that, the written consent of the lead investor is not required in connection with a prepayment made from the proceeds of an Uplist Transaction (as defined below). The Third Notes bear interest on the unpaid principal balance at a rate equal to ten percent (10%) (computed on the basis of the actual number of days elapsed in a 360-day year) per annum accruing from the Third Closing Date until the Third Notes become due and payable at maturity or upon their conversion, acceleration or by prepayment, and may become due and payable upon the occurrence of an event of default under the Third Notes. Any amount of principal or interest on the Third Notes which is not paid when due shall bear interest at the rate of the lesser of (i) eighteen percent (18%) per annum or (ii) the maximum amount allowed by law from the due date thereof until payment in full (the “Default Interest”).

 

-30-

 

The Third Notes are convertible into an aggregate of 76,884 shares of common stock (such shares of common stock, the “Conversion Shares”) at the option of each holder of the Third Notes from the Third Closing Date at the Conversion Price (as defined below) through the later of (i) the Maturity Date and (ii) the date of payment of the Default Amount (as defined in the Third Note); provided, however, certain Third Notes include a provision preventing such conversion if, as a result, the holder, together with its affiliates and any other persons whose beneficial ownership of our common stock would be aggregated with the holder’s, would be deemed to beneficially own more than 4.99% of the outstanding shares of the common stock (the “Notes Ownership Limitation”) immediately after giving effect to the Conversion; and provided further, the holder, upon notice to us, may increase or decrease the Notes Ownership Limitation; provided that (i) the Notes Ownership Limitation may only be increased to a maximum of 9.99% of the outstanding shares of the common stock; and (ii) any increase in the Notes Ownership Limitation will not become effective until the 61st day after delivery of such waiver notice. The initial conversion price of the Third Notes (the “Conversion Price”) shall be equal to $9.14 and may be reduced or increased proportionately as a result of any stock dividends, recapitalizations, reorganizations, and similar transactions. If we fail to deliver the shares of common stock issuable upon a conversion by the Deadline (as defined in the Third Notes), then we are obligated to pay such Third Note holder $5,000 per day in cash for each day beyond the Deadline.

 

The Third Notes contain customary events of default, which include, among other things, (i) our failure to pay when due any principal or interest payment under the Third Notes; (ii) the insolvency of the Company; (iii) delisting of our common stock; (iv) our breach of any material covenant or other material term or condition under the Third Notes; and (v) our breach of any representations or warrants under the Third Notes which cannot be cured within five (5) days. Further, events of default under the Third Notes also include (i) the unavailability of Rule 144 on or after six (6) months after each Third Note’s issuance date; (ii) our failure to deliver the shares of common stock to the Third Note holder upon exercise by such holder of its conversion rights under the Third Note; (iii) our loss of the “bid” price for our common stock and/or a market and such loss is not cured during the specified cure periods; and (iv) our failure to complete an uplist to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American by June 15, 2023 (an “Uplist Transaction”).

 

Upon an event of default, the Third Notes shall become immediately due and payable and we shall pay to each Third Note holder an amount equal to 125% (the “Default Premium”) multiplied by the sum of the outstanding principal amount of the Third Notes plus any accrued and unpaid interest on the unpaid principal amount of the Third Notes to the date of payment, plus any Default Interest and any other amounts owed to the Holder under the Amended SPA (the “Default Amount”); provided that, upon any subsequent event of default not in connection with the first event of default, such holder shall be entitled to an additional five percent (5%) to the Default Premium for each subsequent event of default. At the election of each Third Note holder, the Default Amount may be paid in cash or shares of common stock equal to the Default Amount divided by the Conversion Price at the time of payment.

 

Third Warrants

 

The Third Warrants (i) have an exercise price of $9.94 per share; (ii) have a term of exercise equal to 5 years after their issuance date; (iii) are exercisable immediately after their issuance; and (iv) have a provision preventing the exercisability of such Third Warrant if, as a result of the exercise of the Third Warrant, the holder, together with its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder’s, would be deemed to beneficially own more than either 4.99% or 9.99% of the outstanding shares of common stock (the “Warrant Ownership Limitation”) immediately after giving effect to the exercise of the Third Warrant. The holder, upon notice to us, may increase or decrease the Warrant Ownership Limitation; provided that (i) the Warrant Ownership Limitation may only be increased to a maximum of 9.99% of the outstanding shares of common stock; and (ii) any increase in the Warrant Ownership Limitation will not become effective until the 61st day after delivery of such waiver notice. The number of shares of common stock into which each of the Third Warrants is exercisable and the exercise price therefor are subject to adjustment as set forth in the Third Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise).

 

Second Amended and Restated Registration Rights Agreement

 

On May 15, 2023, we entered into an amendment (the “Second A&R Registration Rights Agreement”) to that certain Amended and Restated Registration Rights Agreement, dated as of January 18, 2023, as amended on April 15, 2023, by and among us and certain institutional and accredited individual investors (as amended, the “A&R Registration Rights Agreement”). Under the Second A&R Registration Rights Agreement, the A&R Registration Rights Agreement was amended to obligate us to file with the SEC a registration statement covering the resale of the Securities issued in the Third Closing.

 

Note Modification Agreements

 

On May 15, 2023, we entered into an amendment (“Amendment No. 5 to the First Notes”) with the holders of our outstanding 2022 Notes, as amended on February 14, 2023, March 10, 2023, March 15, 2023 and April 15, 2023, issued in connection with a private placement financing completed on July 6, 2022 (the “First Closing”). On May 15, 2023, we also entered into an amendment (“Amendment No. 5 to the Second Notes” and, together with Amendment No. 5 to the First Notes, “Amendment No. 5 to the 2022 Notes”) with the holders of our outstanding Second Notes, as amended on February 14, 2023, March 10, 2023, March 15, 2023 and April 15, 2023, issued in connection with a private placement financing completed on January 18, 2023 (the “Second Closing”).

 

-31-

 

Under Amendment No. 5 to the 2022 Notes, the 2022 Notes and Second Notes were amended to extend the date of the completion of the Uplist Transaction from May 15, 2023 to June 15, 2023. As a result of the entry into Amendment No. 5 to the 2022 Notes, and pursuant to the terms of our outstanding Exchanged Notes, the Exchanged Notes were automatically amended to extend the date of completion of an Uplist Transaction from May 15, 2023 to June 15, 2023. In addition, as a result of Amendment No. 5 to the 2022 Notes, each of the First Note Amendment Termination Date set forth in the 2022 Notes, the Second Note Amendment Termination Date set forth in the Second Notes, and the Series Note Amendments Termination Date set forth Amendment No. 1 to the Series 1 Unsecured Convertible Promissory Notes and Amendment No. 1 of the Series 2 Unsecured Convertible Promissory Notes was automatically extended from May 15, 2023 to June 15, 2023.

 

Certain Restrictions on Activities

 

The Amended SPA contains certain restrictions on our ability to conduct subsequent sales of its equity securities and certain business activities. In particular, commencing on the Third Closing Date and until (A) the payment of the Third Notes in full, or full conversion of the Third Notes, and (B) exercise of the Third Warrants in full, we will be prohibited from (i) changing the nature of business, (ii) selling, divesting, acquiring, or changing the structure of any material assets other than in the ordinary course of business; or (iii) negotiating or entering into any variable rate debt transactions that does not contain a floor price that is more than 50% of the closing price of the common stock on the trading day immediately prior to the Third Closing Date; in each instance without each Third Warrant holder’s prior written consent, which shall not be unreasonably withheld.

 

The issuance and sale of the Third Notes, Conversion Shares, Third Warrants, Warrant Shares, and Inducement Shares (collectively, the “Securities”) has not been, and upon issuance was not, registered under the Securities Act, and the Securities may not be offered or sold in the United States absent registration under or exemption from the Securities Act and any applicable state securities laws. The Securities will be issued and sold in reliance upon an exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated under the Securities Act based on the following facts: each of the applicable Investors has represented that it is an accredited investor as defined in Rule 501 promulgated under the Securities Act; that it is acquiring the Securities for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities; we used no advertising or general solicitation in connection with the issuance and sale of the Securities to the applicable Investors; and the Securities will be issued as restricted securities.

 

Receipt of Additional Shareholder Advance

 

On May 18, 2023, the Company received an additional advance from a third party of $350,000, which is expected to be rolled into an anticipated near-term capital raise not related to the prior 2022 Convertible Note Offering.

 

-32-

 

Item 6. Exhibits

 

       

Incorporated by Reference

Exhibit
No.

 

Exhibit Title

Filed

Herewith

Form

Exhibit

No.

File No.

Filing

Date

 

 

 

 

       

10.1

 

Form of Amendment No.2 to Securities Purchase Agreement*

X        

10.2

 

Form of Third Note

X

       

10.3

 

Form of Third Warrant

X

       

10.4

 

Form of Second A&R Registration Rights Agreement

X        

10.5

 

Form of Amendment No. 5 to the First Notes

X        

10.6

 

Form of Amendment No. 5 to the Second Notes

X        
31.1   Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities and Exchange Act of 1934 X        
31.2   Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities and Exchange Act of 1934 X        
32.1   Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by Terrence W. Norchi, President and Chief Executive Officer, and Michael S. Abrams, Chief Financial Officer and Treasurer X        
               

101.INS

 

Inline XBRL Instance Document

         

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

         

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

         

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

         

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

         

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

         

104

 

Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101)

         

 

* Pursuant to Item 601(b)(10) of Regulation S-K, certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Further, the schedules and exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.

 

-33-

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

ARCH THERAPEUTICS, INC.

   
   

Date:  May 22, 2023

By:  

/s/ TERRENCE W. NORCHI, MD

   

Terrence W. Norchi, MD

   

President and Chief Executive Officer

   

(Principal Executive Officer)

     
     

Date: May 22, 2023

By:

/s/ MICHAEL S. ABRAMS

   

Michael S. Abrams

   

Chief Financial Officer

   

(Principal Financial and Accounting Officer)

 

-34-